KR20210154312A - Combination Extract for improving or treating diabetes comprising Rehmanniae Radix Recens, and preparation method thereof - Google Patents
Combination Extract for improving or treating diabetes comprising Rehmanniae Radix Recens, and preparation method thereof Download PDFInfo
- Publication number
- KR20210154312A KR20210154312A KR1020200071087A KR20200071087A KR20210154312A KR 20210154312 A KR20210154312 A KR 20210154312A KR 1020200071087 A KR1020200071087 A KR 1020200071087A KR 20200071087 A KR20200071087 A KR 20200071087A KR 20210154312 A KR20210154312 A KR 20210154312A
- Authority
- KR
- South Korea
- Prior art keywords
- diabetes
- weight
- parts
- complex extract
- extract
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 83
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 78
- 238000002360 preparation method Methods 0.000 title description 14
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 15
- 235000013305 food Nutrition 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 239000009122 Saeng-Ji-Hwang Substances 0.000 claims description 24
- 241000208340 Araliaceae Species 0.000 claims description 18
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 16
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 16
- 235000008434 ginseng Nutrition 0.000 claims description 16
- 230000006872 improvement Effects 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 239000010440 gypsum Substances 0.000 claims description 7
- 229910052602 gypsum Inorganic materials 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- 240000000249 Morus alba Species 0.000 claims description 4
- 235000008708 Morus alba Nutrition 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 241000157835 Gardenia Species 0.000 claims 6
- 239000008280 blood Substances 0.000 abstract description 77
- 210000004369 blood Anatomy 0.000 abstract description 77
- 210000002700 urine Anatomy 0.000 abstract description 44
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 32
- 102000017011 Glycated Hemoglobin A Human genes 0.000 abstract description 22
- 108091005995 glycated hemoglobin Proteins 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 20
- 244000111489 Gardenia augusta Species 0.000 abstract description 16
- 102000004877 Insulin Human genes 0.000 abstract description 16
- 108090001061 Insulin Proteins 0.000 abstract description 16
- 229940125396 insulin Drugs 0.000 abstract description 16
- 230000036541 health Effects 0.000 abstract description 14
- 235000013376 functional food Nutrition 0.000 abstract description 13
- 235000013399 edible fruits Nutrition 0.000 abstract description 9
- 206010023388 Ketonuria Diseases 0.000 abstract description 4
- 208000007976 Ketosis Diseases 0.000 abstract description 4
- 240000005001 Paeonia suffruticosa Species 0.000 abstract description 3
- 235000003889 Paeonia suffruticosa Nutrition 0.000 abstract description 3
- 230000001747 exhibiting effect Effects 0.000 abstract description 3
- 235000018958 Gardenia augusta Nutrition 0.000 abstract description 2
- 244000167230 Lonicera japonica Species 0.000 abstract description 2
- 235000017617 Lonicera japonica Nutrition 0.000 abstract description 2
- 240000006023 Trichosanthes kirilowii Species 0.000 abstract description 2
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 abstract description 2
- 239000003292 glue Substances 0.000 abstract description 2
- 241000736919 Pelodiscus sinensis Species 0.000 abstract 1
- 241000405911 Rehmannia glutinosa Species 0.000 abstract 1
- 241001121987 Scrophularia ningpoensis Species 0.000 abstract 1
- 238000009835 boiling Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 55
- 235000012054 meals Nutrition 0.000 description 34
- 241000411851 herbal medicine Species 0.000 description 31
- 229940079593 drug Drugs 0.000 description 26
- 230000036772 blood pressure Effects 0.000 description 22
- 238000000605 extraction Methods 0.000 description 21
- 239000003826 tablet Substances 0.000 description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
- 239000008103 glucose Substances 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 14
- 235000019640 taste Nutrition 0.000 description 12
- 206010016256 fatigue Diseases 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 210000001525 retina Anatomy 0.000 description 10
- 235000008429 bread Nutrition 0.000 description 9
- 230000002354 daily effect Effects 0.000 description 8
- 238000007689 inspection Methods 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000006187 pill Substances 0.000 description 8
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 7
- 229940029980 drug used in diabetes Drugs 0.000 description 7
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 7
- 201000008980 hyperinsulinism Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 240000001972 Gardenia jasminoides Species 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 230000007937 eating Effects 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 6
- 230000027939 micturition Effects 0.000 description 6
- 229930014626 natural product Natural products 0.000 description 6
- 230000000291 postprandial effect Effects 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 230000002618 waking effect Effects 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 5
- 238000009534 blood test Methods 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000007884 disintegrant Substances 0.000 description 5
- 230000035622 drinking Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000001788 irregular Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000035922 thirst Effects 0.000 description 5
- 229940126673 western medicines Drugs 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- -1 etc. Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 231100000862 numbness Toxicity 0.000 description 4
- 229940124595 oriental medicine Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000019997 soju Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010030216 Oesophagitis Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000001467 acupuncture Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 208000006881 esophagitis Diseases 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 208000024798 heartburn Diseases 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 201000001474 proteinuria Diseases 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000004243 sweat Anatomy 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000548230 Crassostrea angulata Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- GYCKQBWUSACYIF-UHFFFAOYSA-N Ethyl salicylate Chemical compound CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000244342 Ostericum Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000951376 Schizonepeta tenuifolia Species 0.000 description 2
- 208000008765 Sciatica Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 240000007772 Anthriscus sylvestris Species 0.000 description 1
- 235000005749 Anthriscus sylvestris Nutrition 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 241000838298 Aralia continentalis Species 0.000 description 1
- 235000015701 Artemisia arbuscula Nutrition 0.000 description 1
- 235000002657 Artemisia tridentata Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- 241001522252 Crassostrea rivularis Species 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- ZWPRRQZNBDYKLH-VIFPVBQESA-N Gemigliptin Chemical compound C([C@@H](N)CC(=O)N1CC2=C(C(=NC(=N2)C(F)(F)F)C(F)(F)F)CC1)N1CC(F)(F)CCC1=O ZWPRRQZNBDYKLH-VIFPVBQESA-N 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241001570521 Lonicera periclymenum Species 0.000 description 1
- 241001106041 Lycium Species 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 241000361919 Metaphire sieboldi Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 241001529733 Nepeta Species 0.000 description 1
- HXCGUCZXPFBNRD-QVYYAULWSA-N Nodakenin Natural products O(C(C)(C)[C@@H]1Oc2c(cc3c(OC(=O)C=C3)c2)C1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HXCGUCZXPFBNRD-QVYYAULWSA-N 0.000 description 1
- HXCGUCZXPFBNRD-DNLMCPORSA-N Nodakenin Chemical compound CC(C)([C@@H]1OC2=CC=3OC(=O)C=CC=3C=C2C1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HXCGUCZXPFBNRD-DNLMCPORSA-N 0.000 description 1
- 208000007684 Occupational Stress Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241001523579 Ostrea Species 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 241001106477 Paeoniaceae Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000219098 Parthenocissus Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036346 Posterior capsule opacification Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 241000218206 Ranunculus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241001180876 Saposhnikovia Species 0.000 description 1
- 241001180873 Saposhnikovia divaricata Species 0.000 description 1
- 244000007853 Sarothamnus scoparius Species 0.000 description 1
- 241001551940 Scrophularia buergeriana Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 208000030695 Sparse hair Diseases 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229930191920 agosterol Natural products 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000015123 black coffee Nutrition 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960002458 gemigliptin Drugs 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- 206010018388 glossodynia Diseases 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000000910 hyperinsulinemic effect Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- HXCGUCZXPFBNRD-UHFFFAOYSA-N nodakenine Natural products C1C2=CC=3C=CC(=O)OC=3C=C2OC1C(C)(C)OC1OC(CO)C(O)C(O)C1O HXCGUCZXPFBNRD-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 239000011269 tar Substances 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 복합 추출물을 포함하는 당뇨병의 예방 또는 치료용 조성물에 관한 것이다. The present invention relates to a composition for preventing or treating diabetes comprising a complex extract.
당뇨병은 인슐린의 비정상적인 작용으로 인한 대사질환의 일종으로, 혈중 포도당의 농도가 높아지는 고혈당을 특징으로 하며, 고혈당으로 인하여 여러 증상 및 징후를 일으키고 소변에서 포도당을 배출하게 된다. Diabetes mellitus is a type of metabolic disease caused by abnormal action of insulin, and is characterized by hyperglycemia in which the concentration of glucose in the blood increases.
당뇨병은 제1형과 제2형으로 구분되는데, 제1형 당뇨병은 인슐린을 생산하지 못하여 발생하고, 제2형 당뇨병은 인슐린은 분비되나 인슐린의 기능이 떨어져 세포가 인슐린에 대한 저항성(insulin resistance)을 갖게 되어 발생한다. 예컨대, 혈액에 인슐린의 양이 정상으로 생각되는 것보다 높은 상태인 고인슐린혈증에 의해 인슐린 저항성이 발생하고 이에 따라 더 많은 인슐린을 만들어 보충하려고 하는 작용 기전으로 인해 고인슐린혈증으로부터 제2형 당뇨병으로 발전할 수도 있다. 또한, 위와 같은 고인슐린혈증은 혈중 인슐린치가 높은 상태로서, 교감 신경 활성 항진이나 신장에 있어서의 나트륨 흡수 등을 촉진시키는 추가의 문제점을 가진다. Diabetes mellitus is divided into type 1 and type 2, type 1 diabetes is caused by a failure to produce insulin, and type 2 diabetes mellitus insulin is secreted but the function of insulin is poor, causing cells to become resistant to insulin (insulin resistance) is caused by having For example, insulin resistance occurs due to hyperinsulinemia, a condition in which the amount of insulin in the blood is higher than that which is considered normal, and the mechanism of action of making and replenishing more insulin accordingly causes hyperinsulinemia to type 2 diabetes mellitus. may develop In addition, the above hyperinsulinemia is a state of high blood insulin level, and has an additional problem of promoting sympathetic nerve activity enhancement or sodium absorption in the kidneys.
제2형 당뇨병을 치료하기 위한 물질로서는 PPAR-γ 활성제, GLP-1 유도체, DPP-IV 저해제, PTP1B 저해제 등이 주요 당뇨병 치료제들로서 개발되어 있으나 이러한 종래의 약제들은 각각의 기작에 기인한 부작용을 보이고 있다. 예를 들어, 간이나 신장, 근육 및 심장에 대한 독성과 함께 체중증가 증상 등이 대표적인 부작용이라 할 수 있다. 특히, 경구용 혈당강하제로 주로 사용되고 있는 설포닐우레아(sulfonylurea) 제제, 비구아니드(biguanide) 제제 등을 투여할 경우 음식을 먹은 후 혈중 당도는 빨리 증가하는 반면, 투여된 약물로 인한 인슐린의 혈액 내 출현은 상대적으로 느리기 때문에 식후 고혈당, 식사와 식사 사이에는 고인슐린혈증의 문제점을 해결할 수 없다. As a substance for treating type 2 diabetes, PPAR-γ activator, GLP-1 derivative, DPP-IV inhibitor, PTP1B inhibitor, etc. have been developed as major antidiabetic drugs, but these conventional drugs show side effects due to each mechanism. have. For example, toxicity to the liver, kidney, muscle, and heart, along with weight gain, are typical side effects. In particular, when sulfonylurea or biguanide, which are mainly used as oral hypoglycemic agents, are administered, the blood sugar level increases rapidly after eating, whereas the blood sugar level of insulin caused by the administered drug is administered. Because my appearance is relatively slow, the problems of postprandial hyperglycemia and hyperinsulinemia between meals cannot be addressed.
이러한 배경 하에, 식품 또는 약제의 소재로 손쉽게 사용될 수 있는 천연물 소재를 이용하여 당뇨병, 고인슐린혈증을 예방, 개선 또는 치료하기 위한 조성물에 관한 연구 개발이 절실히 필요한 실정이다. Under this background, there is an urgent need for research and development on a composition for preventing, improving or treating diabetes and hyperinsulinemia using natural materials that can be easily used as materials for food or pharmaceuticals.
본 발명은 생지황, 현삼, 괄루인, 목단피, 치자, 인동등 및 별갑교 복합 추출물을 유효성분으로 포함하는 당뇨병의 예방 또는 치료용 약학 조성물을 제공한다.The present invention provides a pharmaceutical composition for the prevention or treatment of diabetes comprising Saengjihwang, Hyeonsam, Gwaruin, Mokdanpi, Gardenia, Indongdung and Byeolgapgyo complex extract as active ingredients.
또한, 본 발명은 생지황, 현삼, 괄루인, 목단피, 치자, 인동등 및 별갑교 복합 추출물을 포함하는 당뇨병의 예방 또는 개선용 식품 조성물을 제공한다.In addition, the present invention provides a food composition for preventing or improving diabetes, comprising the extract of Saengjihwang, Hyeonsam, Gwaruin, Mokdanpi, Gardenia, Indongdung and Byeolgapgyo complex extract.
본 발명자들은 안전성이 우수한 천연 식물 소재를 대상으로 당뇨병을 예방, 개선 및 치료할 수 있는 물질들을 찾기 위해 예의 노력한 결과, 놀랍게도 생지황, 현삼, 괄루인, 목단피, 치자, 인동등 및 별갑교 복합 추출물이 당뇨병, 특히 고인슐린혈증이 관련되는 당뇨병을 효과적으로 예방, 개선 및 치료함을 확인하고 본 발명을 완성하였다. The present inventors have made diligent efforts to find substances that can prevent, improve, and treat diabetes using natural plant materials with excellent safety. Surprisingly, saengjihwang, ginseng, gwaruin, mokdanpi, gardenia, indongdeung, and byeogapgyo complex extract are diabetic. , in particular, confirmed that it effectively prevents, improves and treats diabetes mellitus related to hyperinsulinemia, and completed the present invention.
본 발명은 생지황, 현삼, 괄루인, 목단피, 치자, 인동등 및 별갑교 복합 추출물을 유효성분으로 포함하는 당뇨병의 예방 또는 치료용 약학 조성물을 제공한다.The present invention provides a pharmaceutical composition for the prevention or treatment of diabetes comprising Saengjihwang, Hyeonsam, Gwaruin, Mokdanpi, Gardenia, Indongdung and Byeolgapgyo complex extract as active ingredients.
본 발명의 당뇨병 예방 또는 치료용 약학 조성물은 인슐린의 수준을 크게 낮추고, 혈당및 요당을 개선할 뿐만 아니라 당화혈색소를 개선함으로써 당뇨병의 예방 및 치료에 우수한 효과를 나타낸다. The pharmaceutical composition for preventing or treating diabetes of the present invention significantly lowers the level of insulin, improves blood sugar and urine sugar, as well as improves glycated hemoglobin, thereby exhibiting an excellent effect in preventing and treating diabetes.
본 발명에서 "당뇨병"이란 인슐린의 비정상적인 작용으로 인하여 발생하는 질환이다. 본 발명에서 당뇨병은 모든 종류의 당뇨병을 포함하며, 예를 들어 제1형 당뇨병 또는 제2형 당뇨병을 포함한다. 바람직하게 본 발명의 조성물에 의해 예방 또는 치료되는 당뇨병은 제2형 당뇨병이다. In the present invention, "diabetes" is a disease that occurs due to the abnormal action of insulin. In the present invention, diabetes includes all types of diabetes, for example, type 1 diabetes or type 2 diabetes. Preferably, the diabetes to be prevented or treated by the composition of the present invention is type 2 diabetes.
제2형 당뇨병은 혈중 인슐린치가 높은 상태가 유지되는 고인슐린혈증으로 인하여 인슐린 저항성을 발생시킴으로써 발병될 수 있다. 본 발명에 따른 조성물은 고인슐린혈증 상태에서 혈중 인슐린 농도를 크게 낮추고, 혈당 및 요당을 감소시키며 당화혈색소를 개선하며 케톤뇨의 수치를 안정화 시킴으로써 제2형 당뇨병에 대해 우수한 효과를 나타낸다. Type 2 diabetes can be caused by developing insulin resistance due to hyperinsulinemia in which blood insulin levels remain high. The composition according to the present invention shows an excellent effect on type 2 diabetes by significantly lowering the blood insulin concentration in a hyperinsulinemic state, reducing blood sugar and urine sugar, improving glycated hemoglobin, and stabilizing the level of ketonuria.
본 발명에 있어서 생지황(Rehmanniae Radix Recens)은 현삼과의 신선한 뿌리로, 가을에 채취하여 노두, 뿌리털 및 흙모래를 제거하고 신선한 것을 쓰거나 80%까지 마르도록 홍건한 것을 쓴다. 원기둥모양~방추형을 이루고 길이 5~15cm, 지름 0.8~2cm로서 더러는 꺾이어졌거나 구부러진 것도 있다. 바깥 면은 황적색~황적갈색을 띠고 가로로 깊이 패어진 골이 있다. 질은 매우 연하여 잘 꺾인다. 꺾은 면은 평탄하며 목부는 흰색, 피부는 연한 황적색이다. 특유한 냄새가 약간 있고 맛은 달고 약간 쓰다.In the present invention, Saengjihwang (Rehmanniae Radix Recens) is a fresh root of the ginseng family, collected in autumn to remove outcrops, root hairs, and soil sand, and uses fresh or red-dried ones to dry up to 80%. It forms a cylindrical-fusiform shape, with a length of 5-15cm and a diameter of 0.8-2cm, and some are bent or bent. The outer surface is yellowish-red to yellow-reddish-brown, and has horizontally deep grooves. The quality is very soft and bends easily. The cut surface is flat, the neck is white, and the skin is light yellowish red. It has a characteristic odour, and the taste is sweet and slightly bitter.
본 발명에 있어서 현삼(Scrophularia buergeriana)은 중대(重臺) ·현대(玄臺) ·귀장(鬼藏) ·축마(逐馬)라고도 한다. 산지에서 자란다. 뿌리가 굵어지고 높이 80?m로, 단면은 사각형이며 가지가 없다. 잎은 마주달리고 긴 난형이며 끝이 뾰족하고 가장자리에 톱니가 있으며 잎자루는 짧다. 꽃은 8~9월에 피고 황록색이며 취산꽃차례에 달린다. 꽃받침은 5개로 갈라지고 화관은 찌그러진 단지처럼 생겼으며 가장자리는 5개로 갈라진다. 4개의 수술 중에서 2개가 길고 삭과(果)는 난형이다. 한방에서는 일반적으로 뿌리를 현삼이라고 한다. In the present invention, Hyun ginseng ( Scrophularia buergeriana ) is also called middle (weight) · modern (玄臺) · gwijang (鬼藏) · chukhor (逐 horse). It grows in mountainous areas. The root is thick and 80?m high, and the cross section is square and there are no branches. The leaves are opposite, long ovate, pointed at the end, and sawtooth on the edge, and the petiole is short. Flowers bloom in August-September and are yellow-green in color and hang on inflorescences. The calyx is divided into 5 pieces, and the corolla is shaped like a crushed jar, and the edge is divided into 5 pieces. Among the 4 stamens, 2 are long and capsules are ovate. In oriental medicine, the root is generally called Hyeonsam.
본 발명에 있어서 괄루인(Trichosanthes kirilowii)은 박과의 하늘타리, 노랑하늘타리의 씨를 말하며, 하늘타리는 덩굴성식물이며 나무에 달린 열매와 땅에서 열리는 열매를 합쳐서 부르는 과라(果)가 음이 변하여 괄루(樓)가 되었다고 한다. 이 약은 냄새가 없고 맛은 달고 쓰며 성질은 차다.In the present invention, Gwaruin ( Trichosanthes kirilowii ) refers to the seeds of Cucumber serrata and yellow haremaceae, which are vines, and the Guara (果), which is a combination of the fruit on a tree and the fruit that grows on the ground, changes the sound and changes the tone.樓) is said to have been This medicine is odorless, tastes sweet and bitter, and has a cold nature.
본 발명에 있어서 목단피(Paeonia suffruticosa)는 작약과의 모란(Paeonia suffruticosa Andrews)의 뿌리껍질로 만든 약재(한국). 중국과 일본도 우리나라와 같다. 이 약은 특이한 냄새가 있으며 맛은 조금 쓰고 매우며 성질은 약간 차다.Mokdanpi in the present invention ( Paeonia suffruticosa ) is a medicinal material made from the root bark of the peony family (Paeonia suffruticosa Andrews) (Korea). China and Japan are the same as Korea. This medicine has a characteristic odor, and the taste is slightly bitter and very cold in nature.
본 발명에 있어서 치자(Gardenia jasminoides)는 치자 나무의 익은 열매를 말린것이다. 가을에 익은 열매를 따서 말리고, 맛은 쓰고 성질은 차다. Gardenia (Gardenia jasminoides ) in the present invention is a dried fruit of the gardenia tree. The ripe fruits are picked and dried in autumn, and the taste is bitter and the nature is cold.
본 발명에 있어서 인동등(Lonicera japonica) 은 인동덩굴의 줄기와 잎을 말린 것이다. 각지의 산기슭과 밭둑에서 자란다. 늦여름부터 가을 사이에 줄기를 거두어 햇볕에 말린다. 맛은 달고 성질은 차다.In the present invention, Lonicera japonica ) is the dried stem and leaves of honeysuckle. It grows in the foothills and fields of various places. The stems are harvested between late summer and autumn and dried in the sun. The taste is sweet and the nature is cold.
본 발명에 있어서 별갑교는 자라 등딱지를 깨끗이 씻어서 가마에 넣고 물을 넣은 다음 푹 달여서 거르는 조작을 3~5번 거듭한다. 거른 액을 합쳐서 아교가 되도록 졸여 식혀서 잘게 썰어 그늘에서 말린 것을 말한다. In the present invention, byeolgapgyo is washed cleanly the carapace of the larvae, put in a kiln, put in water, and then thoroughly decocted and filtered 3 to 5 times. It refers to a product that combines the filtered liquid, boils it to become a glue, cools it, cuts it into small pieces, and then dried it in the shade.
본 발명에 따른 복합 추출물은 추가의 한약재 성분들을 더 포함할 수 있다. 이러한 추가 성분들은 환자의 한의학적 상태를 고려하여 1이상 추가될 수 있는 것이며, 복합 추출물의 당뇨 개선 효과를 보다 증진 시킬 수 있다. The complex extract according to the present invention may further include additional herbal ingredients. One or more of these additional ingredients can be added in consideration of the patient's oriental medical condition, and the diabetes improvement effect of the complex extract can be further enhanced.
구체적으로, 석고, 모려, 형개, 방풍, 강활, 독활, 전호, 지골피 및 목통으로 이루어진 군으로부터 선택되는 어느 하나 이상을 더 포함할 수 있다. Specifically, it may further include any one or more selected from the group consisting of gypsum, moryeo, hyeonggae, windbreak, ganghwal, dokhwal, jeonho, phalanx and moktong.
본 발명에 있어서 석고는 성질은 차며 맛은 맵고 독이 없다. 동의보감 상에서는 돌림병으로 머리가 아프고 몸에 열이 나는 것과 3초로 열이 몹시 나는 것, 피부열, 입이 마르고 혀가 타며 목구멍이 다는 증을 낫게 한다. 또 소갈증을 낫게 하고 해기(解肌)해서 땀을 내게 하고 위화(胃火)를 사한다고 알려져 있다. In the present invention, gypsum is cold in nature, spicy in taste, and non-toxic. In Donguibogam, it cures headache and body fever due to dolrimbyeong, fever in 3 seconds, skin fever, dry mouth, burning tongue, and sore throat. It is also said to relieve thirst, make you sweat, and relieve stomach upset.
본 발명에 있어서 모려는 Crassostrea gigas, Ostera rivularis, Ostrea gigas, Ostrea rivularis, Ostrea talienwhanensis의 패각(貝殼)으로써 음액(陰液)을 수렴하고 양(陽)의 기운을 키우며 담을 멈추게 하고 정(精)을 수렴하며 담(痰)을제거하는 효능이 있는 약재이다. In the present invention, Moryae is the shell of Crassostrea gigas, Ostera rivularis, Ostrea gigas, Ostrea rivularis, and Ostrea talienwhanensis, which converges yin and yang, stops the wall, and purifies the body. It is a medicinal agent that has the effect of astringent and removing phlegm.
본 발명에 있어서 형개(Schizonepeta tenuifolia)는 형개(정가) Schizonepeta tenuifolia Briq. 또는 Nepeta japonica Maxim.의 전초를 말린 것이다. 각지에서 심는다. 여름철 꽃이 필 때 전초를 베어 바람이 잘 통하는 그늘에서 말린다. 맛은 맵고 쓰며 성질은 따뜻하다. Hyeonggae in the present invention ( Schizonepeta tenuifolia ) is Hyeonggae (list price) Schizonepeta tenuifolia Briq. Or Nepeta japonica Maxim. is dried out of the planted everywhere. When the flowers bloom in the summer, cut the outpost and dry it in the shade with good ventilation. The taste is spicy and bitter, and the nature is warm.
본 발명에 있어서 방풍(Saposhnikovia divaricata Sc)은 Saposhnikovia divaricata Schischkin (산형과 Umbelliferae)의 뿌리이다. 별명으로 관방풍(關防風) 또는 동방풍(東防風)이라고도 하는데 기록에 따르면 중국에서 방풍의 정품으로 주로 이용되는 품목이다. 뿌리로 가늘고 긴원뿔 모양이며 아래로 갈수록 점점 가늘어지고, 길이 15~20cm, 지름 0.7~1.5cm이다. 바깥 면은 연한 갈색을 띠며 세로주름이 많고, 가는 뿌리자국도 있다. 머리부분에 남아있는 엽기는 빗자루 모양이고 엽기를 제거한 것은 뿌리의 머리 부분에 고리무늬가 밀집하여 지렁이의 머리부분처럼 보인다. 몸체는 가볍고, 질은 부드러워 자르기 쉽다. 자른 면은 피부가 연한 갈색이고 여러개의 벌어진 틈이 있으며, 목부는 연한 노란색이고 전체적으로 동그란 눈망울처럼 보인다. 특유한 냄새가 있고 맛은 약간 달다.Windbreak in the present invention ( Saposhnikovia divaricata Sc) is Saposhnikovia It is the root of divaricata Schischkin (Umbelliferae). It is also known as Guanbangpung (關防wind) or Eastern Bangpung (東防wind), and according to records, it is an item mainly used as a genuine windbreaker in China. It has a long, conical shape with a root, and becomes progressively thinner as it goes down, and is 15-20 cm long and 0.7-1.5 cm in diameter. The outer surface is light brown, and there are many vertical wrinkles, and there are also thin root marks. The bizarre parts that remain on the head are in the shape of a broom, and the ones with the bizarre parts removed have a dense ring pattern on the head of the root and look like the head of an earthworm. The body is light, the quality is soft, and it is easy to cut. On the cut side, the skin is light brown, there are several gaps, the neck is light yellow, and it looks like round eyes as a whole. It has a characteristic odor and the taste is slightly sweet.
본 발명에 있어서 강활(Ostericum praeteritum)은 미나리과 식물인 강호리 Ostericum praeteritum Kitag.의 뿌리를 말린 것이다. 우리 나라 중부 이북 특히 강원도의 깊은 산골짜기에서 자라며 각지에서 심기도 한다. 가을이나 봄에 뿌리를 캐서 물에 씻어 햇볕에 말린다. 맛은 쓰고 매우며 성질은 약간 따뜻하다.In the present invention, Ganghwal ( Ostericum praeteritum ) is a dried root of Ganghori Ostericum praeteritum Kitag. It grows in the deep valleys of Gangwon-do, especially in the central and northern parts of our country, and is also planted in various places. Dig up the roots in autumn or spring, wash them in water and dry them in the sun. The taste is bitter and bitter, and the nature is slightly warm.
본 발명에 있어서 독활(Aralia continentalis)은 두릅나무과에 속하는 다년생 초본 식물로 높이는 1.5m 정도로 꽃을 제외한 전체에 짧은 털이 드문드문 있다. 잎은 어긋나고, 길이 50 ~ 100 ㎝로서 기수이회우상복엽(奇數二回羽狀複葉)이다. 작은 잎은 난형(卵形) 또는 타원형으로 끝이 뾰족하다. 길이 5-30㎝, 너비 3-20㎝로서 양면에 털이 드문드문 있다. 7, 8월에 가지와 원줄기 끝 또는 윗부분의 엽맥(葉脈)에서 큰 원추화서(圓錐花序:원뿔모양의 꽃차례)가 자란다. 꽃은 1가화(一家花: 암·수의 꽃이 한 가지에 핌)로서 연한 녹색이다. 열매는 9, 10월에 익는다.In the present invention, poisoning ( Aralia continentalis ) is a herbaceous perennial plant belonging to the family Araliaceae, with a height of 1.5 m and sparsely short hairs throughout except for flowers. The leaves are alternate phyllotaxis, 50 ~ 100 cm long, and are bipolar right-sided bi-lobed leaves. The small leaves are ovate or oval with a sharp tip. It is 5-30cm long and 3-20cm wide, with sparse hairs on both sides. In July and August, large panicles (conical inflorescences) grow on branches and at the tip or upper leaf veins of main stems. The flowers are light green as a single flower (one family flower: male and female flowers bloom on one branch). The fruits ripen in September and October.
본 발명에 있어서 전호(Anthriscus sylvestris)는 미나리과에 속하는 다년생 초본식물이다. 숲이나 약간 습기가 있는 곳에서 잘 성장한다. 꽃은 5∼월에 희게 피고, 7∼월에 열매를 맺는다. 열매에 누른빛이 돌고 전체에 털이 있는 털전호도 야생한다. 전호는 특히 뿌리가 잘 발달되어 약으로 많이 활용하고 있는데 약명도 전호라고 한다. 약효성분은 후로쿠마린류인 노다케닌과 스폰게스테론·마니톨·정유 등이 알려져 있다. 약성은 약간 차고 독이 없으며, 맛은 쓰고 맵다.In the present invention, Jeonho ( Anthriscus sylvestris ) is a herbaceous perennial plant belonging to the family Buttercup. Grows well in forests or slightly damp places. Flowers bloom white in May-May and bear fruit in July-June. The fruit has a yellowish color, and the hairy sagebrush is also wild. Jeonho is particularly well-developed with roots and is widely used as a medicine. The medicinal ingredients are known as nodakenin, which is a furocumarin, and spongesterone, mannitol, and essential oil. Weakness is slightly cold and non-toxic, and the taste is bitter and spicy.
본 발명에 있어서 지골피(Lycium chinense)는 구기자나무의 뿌리 껍질이다. 뿌리껍질로 원통 모양~반원통 모양 또는 조각이며, 길이 3~10cm, 너비 0.5~1.5cm, 두께 0.1~0.3cm이다. 바깥 면은 회황색~등황색으로 거칠며 불규칙하게 세로로 찢어진 무늬가 있고 주피는 비늘 모양으로 벗겨지기 쉽다. 안쪽 면은 황백색~회황색이고 비교적 평탄하며 가는 세로무늬가 있다. 꺾인 면은 회백색~황갈색을 나타내고 섬유성은 아니며 질은 가볍고 거칠다. 특유한 냄새가 있고 맛은 약간 달며 후에 쓰다.In the present invention, the phalanx ( Lycium) chinense ) is the root bark of Goji berry. The root bark is cylindrical-semi-cylindrical or fragmented, 3-10 cm long, 0.5-1.5 cm wide, and 0.1-0.3 cm thick. The outer surface is gray-yellow to orange-yellow, rough, irregularly with vertical torn patterns, and the bark is scaly and easy to peel off. The inner surface is yellowish-white to gray-yellow, relatively flat, with thin vertical patterns. The cut side is grayish white to yellowish brown, not fibrous, and the quality is light and rough. It has a characteristic odour, and the taste is slightly sweet and bitter later.
본 발명에 있어서 목통(Akebiae Caulis)은 으름덩굴과의 줄기로서 주피를 제거한 것이다. 주피를 제거한 줄기로 원기둥 모양이며 보통 비틀려 굽어 있고, 길이 30~70cm, 지름 0.5~2cm이다. 바깥쪽은 황백색~황갈색이고, 세로로 난 골이 아주 많으며, 마디가 있는 곳은 팽대되어 있기도 하고 곁가지가 절단된 흔적이 보이기도 한다. 주피가 남아있는 것은 회갈색이고 원형 또는 세로로 긴 타원형의 피목이 있다. 질은 가볍고 견실하며 자르기 어렵다. 양 쪽에 잘린 면은 피부가 어두운 회갈색이고 목부는 연한 갈색의 도관부와 회백색의 수선이 번갈아가며 방사상으로 배열하고 있다. 수는 연한 회황색이고 뚜렷하다. 냄새가 거의 없고 맛은 약간 아리다.In the present invention, the neck tube ( Akebiae Caulis ) is a stem of the creeper family with the bark removed. A stem with bark removed, cylindrical, usually twisted, and 30-70 cm long and 0.5-2 cm in diameter. The outside is yellowish-white to yellowish-brown, and there are many vertical troughs, and the places where there are nodes are enlarged and there are also traces of cutting of side branches. What remains is grayish-brown and has a round or vertically long oval bark. The quality is light, firm, and difficult to cut. On both sides of the cut side, the skin is dark grayish-brown, and the neck has a light brown conduit and a grayish-white waterline alternately arranged radially. The numbers are pale grayish-yellow and distinct. There is almost no odor and the taste is slightly bitter.
본 발명의 용어 "추출물"이란, 상기 언급된 천연물의 꽃, 전초, 잎, 줄기, 종자, 열매, 뿌리 및/또는 그들의 분쇄물을 추출 처리하여 얻어지는 추출액, 상기 추출액의 희석액이나 농축액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다.As used herein, the term "extract" refers to an extract obtained by extracting and processing the flowers, herbs, leaves, stems, seeds, fruits, roots, and/or pulverized products of the above-mentioned natural products, dilutions or concentrates of the extracts, and the extracts. It includes extracts of all formulations that can be formed using the extract itself and the extract, such as a dried product obtained by drying, a prepared product or purified product of the extract, or a mixture thereof.
상기 복합 추출물은 통상의 추출물 제조방법에 따라 상기 언급된 천연물 또는 이를 가공한 약재로부터 추출되어 제조될 수 있다. The complex extract may be prepared by extracting from the above-mentioned natural product or a drug processing it according to a conventional extract preparation method.
예를 들어, 상기 언급된 천연물 또는 이의 가공 약재의 무게에 대하여 약 1 내지 20 배, 바람직하게는 약 3 내지 10 배의 1차 추출용매, 바람직하게는 물, C1내지 C4의 저급알코올 (예컨대, 메탄올, 에탄올, 프로판올, 이소프로판올, 부탄올 등) 또는 이들의 혼합용매로 추출함으로써 수행할 수 있다. 추출은 당 분야에 알려진 추출방법, 예컨대, 냉침, 열수추출, 초음파 추출, 환류 냉각 추출 등의 방법으로 수행될 수 있으나, 이에 국한되지 않는다. 추출 온도는 당업자가 추출 방법에 적절한 다양한 온도 범위를 채택할 수 있으며, 예를 들어, 20 ℃ 내지 100 ℃ 등에서 수행될 수 있으나, 이에 국한되지 않는다. 또한, 추출시간은 추출방법에 따라 상이하며, 당업자가 적절한 추출시간을 채택할 수 있으며, 이에 국한되지 않으나, 약 1 시간 내지 10 일의 범위에서 단회 또는 복수회로 수행될 수 있다. 상기 1차 추출용매로 추출을 수행하여 얻어진 추출물은 통상의 방법에 따라 여과하여 불순물을 제거한 액상 형태로 얻거나, 얻어진 액상 형태의 추출물을 통상의 방법에 따라 감압농축 및/또는 건조하여 분말 형태로 얻을 수 있다.For example, about 1 to 20 times, preferably about 3 to 10 times the weight of the aforementioned natural product or a processed drug thereof, the primary extraction solvent, preferably water, C 1 to C 4 lower alcohol ( For example, extraction with methanol, ethanol, propanol, isopropanol, butanol, etc.) or a mixed solvent thereof can be carried out. Extraction may be performed by an extraction method known in the art, for example, cold extraction, hot water extraction, ultrasonic extraction, reflux cooling extraction, etc., but is not limited thereto. The extraction temperature may be adopted by those skilled in the art in various temperature ranges suitable for the extraction method, for example, it may be carried out at 20 ℃ to 100 ℃, etc., but is not limited thereto. In addition, the extraction time varies depending on the extraction method, and a person skilled in the art may adopt an appropriate extraction time, but is not limited thereto, but may be performed single or multiple times in the range of about 1 hour to 10 days. The extract obtained by performing extraction with the primary extraction solvent is obtained in a liquid form from which impurities are removed by filtration according to a conventional method, or the obtained liquid extract is concentrated and/or dried under reduced pressure according to a conventional method to obtain a powder form can be obtained
또한, 상기 추출공정은 필요에 따라, 유효성분의 함량이 높은 분획을 얻는 단계를 더 포함할 수 있다. 즉, 상기 1차 추출용매로 추출하여 얻어진 추출물을 물에 분산시킨 후, 적절한 2차 추출용매, 예컨대, 수포화 C1- C4 의 알코올로 추출하는 단계를 수행하여 유효성분의 함량을 증진시킬 수 있다. In addition, the extraction process may further include, if necessary, obtaining a fraction having a high content of the active ingredient. That is, after dispersing the extract obtained by extraction with the primary extraction solvent in water, extraction with an appropriate secondary extraction solvent, for example, saturated C 1 -C 4 alcohol, to enhance the content of the active ingredient. can
또한 본 발명에 따른 복합 추출물은 각각의 천연물 또는 이를 가공한 약재 각각을 추출한 후 이를 혼합한 것일 수 있고, 또는 각각의 천연물 또는 이를 가공한 약재를 혼합한 후에 이에 추출방식을 적용하여 추출한 것일 수도 있다. In addition, the complex extract according to the present invention may be obtained by extracting each natural product or each of the processed medicines and mixing them, or may be extracted by applying an extraction method to each natural product or after mixing the processed medicines. .
본원 발명의 일실시양태에 따르면, 상기 언급된 천연물 또는 이를 가공한 약재를 물에 넣은 후 80 내지 100℃의 약탕기에서 중탕을 통해 제조하는 것일 수 있다. According to one embodiment of the present invention, it may be prepared through a bath in a yaktanggi at 80 to 100 ℃ after putting the above-mentioned natural product or a processed medicine thereof into water.
또한, 상기 중탕에 의해 제조된 복합 추출물 약제를 저압 농축기를 통해 압력을 낮추어 가열하여 물을 증발시킴으로써 농축할 수도 있다. In addition, the compound extract drug prepared by the bath may be concentrated by heating by lowering the pressure through a low-pressure concentrator to evaporate water.
이에 따라 본 발명에 따르면, (a) 생지황, 현삼, 괄루인, 목단피, 치자, 인동등 및 별갑교를 물에 넣고 80 내지 100℃로 1 내지 5시간 가열 추출하는 단계;를 포함하는 복합 추출물의 제조 방법을 제공한다. Accordingly, according to the present invention, (a) Saengjihwang, Hyeonsam, Gwaruin, Mokdanpi, Gardenia, Indong, etc. and Byeolgapgyo are put in water and extracted by heating at 80 to 100° C. for 1 to 5 hours; A manufacturing method is provided.
본 발명에 따른 복합추출물의 제조 방법은 (b) 저압 농축기를 통해 압력을 낮추어 가열하여 물을 증발시켜 상기 (a)단계의 복합 추출물을 농축시키는 단계를 더 포함할 수 있다. 상기 저압 농축기를 이용한 농축은 60 내지 80℃에서 압력을 낮추어 물을 증발시키면서 추출하는 것일 수 있다. The method for producing a complex extract according to the present invention may further include (b) concentrating the complex extract of step (a) by heating and evaporating water by lowering the pressure through a low-pressure concentrator. Concentration using the low pressure concentrator may be extraction while evaporating water by lowering the pressure at 60 to 80 ℃.
본 발명에 따른 상기 (a) 단계의 복합 추출물의 제조는 생지황, 현삼, 괄루인, 목단피, 치자, 인동등 및 별갑교에 더하여, 석고, 모려, 형개, 방풍, 강활, 독활, 전호, 지골피 및 목통로 이루어진 군으로부터 선택되는 하나 이상을 더 포함할 수 있다.The preparation of the complex extract of step (a) according to the present invention is, in addition to Saengjihwang, Hyeonsam, Gwaruin, Mokdanpi, Gardenia, Indongdeung and Byeolgapgyo, gypsum, Moryeo, Hyeonggae, Bangpung, Ganghwal, Dokhwal, Jeonho, Jigolpi and It may further include one or more selected from the group consisting of the neck.
본 발명에서 사용되는 용어, "예방"은 본 발명의 상기 조성물을 개체에 투여하여 당뇨병을 억제하거나 지연시키는 모든 행위를 의미한다.As used herein, the term “prevention” refers to any action of inhibiting or delaying diabetes by administering the composition of the present invention to an individual.
본 발명에서 사용되는 용어, "치료"는 본 발명의 상기 조성물을 개체에 투여하여 당뇨병 증세가 호전되도록 하거나 이롭게 되도록 하는 모든 행위를 의미한다.As used herein, the term “treatment” refers to any action for improving or benefiting diabetic symptoms by administering the composition of the present invention to an individual.
본 발명에 따른 복합 추출물은 생지황, 현삼, 괄루인, 목단피, 치자, 인동등 및 별갑교를 물 100 중량부에 대해 각각 생지황 1 내지 5 중량부, 현삼 1 내지 5 중량부, 괄루인 0.5 내지 4 중량부, 목단피 0.5 내지 3 중량부, 치자 0.3 내지 3, 인동등 0.3 내지 3 중량부, 별갑교 0.1 내지 2중량부로 포함하는 것이 바람직할 수 있다. The complex extract according to the present invention contains 1 to 5 parts by weight of Saengjihwang, 1 to 5 parts by weight of Hyeonsam, 0.5 to 4 parts by weight of Saengjihwang, Hyeonsam, Gwaruin, Mokdanpi, Gardenia, Indongdang and Byeolgapgyo with respect to 100 parts by weight of water, respectively. It may be preferable to include it in an amount of 0.5 to 3 parts by weight, 0.5 to 3 parts by weight of mulberry skin, 0.3 to 3 parts by weight of gardenia, 0.3 to 3 parts by weight of ginseng, etc., and 0.1 to 2 parts by weight of byeolgap bridge.
보다 바람직하게 물 100 중량부에 대해 약 생지황 2.5 중량부, 현삼 2.25 중량부, 괄루인 1.75 중량부, 목단피 1.25 중량부, 치자 0.94 중량부, 인동등 0.94 중량부, 별갑교 0.38 중량부일 수 있다. More preferably, about 100 parts by weight of water, about 2.5 parts by weight of saengjihwang, 2.25 parts by weight of ginseng, 1.75 parts by weight of gwaruin, 1.25 parts by weight of mulberry skin, 0.94 parts by weight of gardenia, 0.94 parts by weight of ginseng, etc., 0.38 parts by weight of byeolgap bridge.
또한, 석고, 모려, 형개, 방풍, 강활, 독활, 전호, 지골피 및 목통로 이루어진 군으로부터 선택되는 하나 이상을 더 포함할 수 있으며, 각각의 상기 성분은 물 100 중량부에 대해 각각 0.2 내지 6중량부 만큼을 포함하는 것이 바람직하다. 이들 각각의 성분은 한의학적 환자의 상태에 따라 적절 수준으로 포함될 수 있다. In addition, it may further include one or more selected from the group consisting of gypsum, moryeo, hyeonggae, windbreak, ganghwal, dokhwal, jeonho, phalanx and moktong, each of the components 0.2 to 6 parts by weight based on 100 parts by weight of water. It is preferable to include as much as a part. Each of these components may be included at an appropriate level according to the condition of the oriental medicine patient.
본 발명의 복합 추출물을 유효성분으로 함유하는 조성물의 총 중량에 대하여 0.1 내지 95 중량%로 복합 추출물을 포함하는 것이 바람직하나 이에 한정되지 않는다.It is preferable to include the complex extract in an amount of 0.1 to 95% by weight based on the total weight of the composition containing the complex extract of the present invention as an active ingredient, but is not limited thereto.
본 발명의 약학 조성물은 약제학적으로 허용가능한 담체를 포함할 수 있으며, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제제화될 수 있다.The pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier, and each of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., oral dosage forms, external preparations, suppositories, and It may be formulated in the form of a sterile injectable solution.
상기 약제학적으로 허용가능한 담체는 당업계에서 통상적으로 사용되는 것들, 예컨대 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 포함하나 이에 국한되지 않는다. 또한, 본 발명의 약학 조성물은 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제, 기타 약제학적으로 허용가능한 첨가제를 포함한다.The pharmaceutically acceptable carriers include those commonly used in the art, such as lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In addition, the pharmaceutical composition of the present invention includes a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, and other pharmaceutically acceptable additives.
본 발명의 약학 조성물이 경구용 고형 제제로 제제화된 경우 정제, 환제, 산제, 과립제, 캡슐제 등을 포함하며, 이러한 고형제제는 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (calcium carbonate), 수크로스(sucrose) 또는 락토즈, 젤라틴 등을 포함할 수 있으며, 마그네슘 스테아레이트, 탈크 같은 윤활제 등을 포함하나 이에 국한되지 않는다. When the pharmaceutical composition of the present invention is formulated as a solid preparation for oral use, it includes tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one or more excipients, for example, starch, calcium carbonate, It may include sucrose or lactose, gelatin, and the like, and includes, but is not limited to, lubricants such as magnesium stearate and talc.
본 발명의 약학 조성물이 경구용 액상 제제화된 경우 현탁제, 내용액제, 유제, 시럽제 등을 포함하며, 물, 리퀴드 파라핀 등의 희석제, 습윤제, 감미제, 방향제, 보존제 등을 포함하나 이에 국한되지 않는다. When the pharmaceutical composition of the present invention is formulated as a liquid formulation for oral use, it includes suspensions, solutions, emulsions, syrups, and the like, and includes, but is not limited to, water, diluents such as liquid paraffin, wetting agents, sweeteners, fragrances, preservatives, and the like.
본 발명의 약학 조성물이 비경구용 제제화된 경우 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제를 포함하며, 비수성 용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르류 등을 포함하나 이에 국한되지 않는다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있으나 이에 국한되지 않는다.When the pharmaceutical composition of the present invention is formulated for parenteral use, it includes sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories, and non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, olive. vegetable oils such as oils, injectable esters such as ethyl oleate, and the like. As a base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, etc. may be used, but are not limited thereto.
본 발명의 약학 조성물에 함유되는 복합 추출물의 투여량은 환자의 상태 및 체중, 연령, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 예를 들면, 복합 추출물은 1일 0.0001 내지 100 mg/kg으로, 바람직하게는 0.001 내지 10 mg/kg의 용량으로 투여할 수 있으며, 상기 투여는 하루에 한번 또는 수회 나누어 투여할 수도 있다.The dosage of the complex extract contained in the pharmaceutical composition of the present invention varies depending on the patient's condition and weight, age, degree of disease, drug form, administration route and period, but may be appropriately selected by those skilled in the art. For example, the complex extract may be administered at a dose of 0.0001 to 100 mg/kg per day, preferably 0.001 to 10 mg/kg, and the administration may be administered once or in several divided doses per day.
본 발명의 약학조성물은 랫트, 마우스, 가축, 인간 등의 포유동물에 다양한 경로로, 예를 들면, 경구, 복강 또는 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관 내 주사에 의해 투여될 수 있다. The pharmaceutical composition of the present invention may be administered to mammals such as rats, mice, livestock, and humans by various routes, for example, oral, intraperitoneal or intravenous, intramuscular, subcutaneous, intrauterine intrathecal or intracerebrovascular injection. .
본 발명은 또한 생지황, 현삼, 괄루인, 목단피, 치자, 인동등 및 별갑교 복합 추출물을 유효성분으로 포함하는 당뇨병의 예방 또는 개선용 식품 조성물을 포함한다.The present invention also includes a food composition for preventing or improving diabetes, comprising Saengjihwang, Hyeonsam, Gwaruin, Mokdanpi, Gardenia, Indongdung and Byeolgapgyo complex extract as active ingredients.
본 발명의 식품 조성물은 건강기능식품으로서 사용될 수 있다. 상기 "건강기능식품"이라 함은 건강기능식품에 관한 법률에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다.The food composition of the present invention can be used as a health functional food. The term "health functional food" means a food manufactured and processed using raw materials or ingredients useful for the human body in accordance with the Health Functional Food Act, and "functionality" refers to the structure and function of the human body. It refers to ingestion for the purpose of obtaining useful effects for health purposes such as regulating nutrients or physiological effects.
본 발명의 식품 조성물은 통상의 식품 첨가물을 포함할 수 있으며, 상기 "식품 첨가물"로서의 적합 여부는 다른 규정이 없는 한, 식품의약품안전처에 승인된 식품 첨가물 공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다. The food composition of the present invention may contain conventional food additives, and the suitability as the "food additive" is determined according to the general rules and general test methods of food additives approved by the Ministry of Food and Drug Safety, unless otherwise specified. It is judged according to the standards and standards related to the item.
상기 "식품 첨가물 공전"에 수재된 품목으로는 예를 들어, 케톤류, 글리신, 구연산칼륨, 니코틴산, 계피산 등의 화학적 합성물, 감색소, 감초추출물, 결정셀룰로오스, 고량색소, 구아검 등의 천연첨가물, L-글루타민산나트륨 제제, 면류첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합제제류들을 들 수 있다.The items listed in the "Food Additives Code" include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid; Mixed preparations such as sodium L-glutamate preparation, noodle-added alkali agent, preservative agent, and tar color agent can be mentioned.
본 발명의 식품 조성물은 조성물 총 중량에 대하여 복합 추출물을 0.01 내지 95 중량%, 바람직하게는 1 내지 80 중량%로 포함할 수 있다. 본 발명의 식품 조성물에 함유되는 복합 추출물은 상기 약학 조성물의 제조에서 언급된 추출방법과 동일한 방법으로 얻어질 수 있다. The food composition of the present invention may include 0.01 to 95% by weight of the complex extract, preferably 1 to 80% by weight, based on the total weight of the composition. The complex extract contained in the food composition of the present invention can be obtained by the same method as the extraction method mentioned in the preparation of the pharmaceutical composition.
또한, 본 발명의 식품 조성물은 당뇨병의 예방 및/또는 개선을 목적으로, 정제, 캡슐, 분말, 과립, 액상, 환 등의 형태로 제조 및 가공할 수 있다.In addition, the food composition of the present invention may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc. for the purpose of preventing and/or improving diabetes.
예를 들어, 상기 정제 형태의 건강기능식품은 복합 추출물, 부형제, 결합제, 붕해제, 및 다른 첨가제와의 혼합물을 통상의 방법으로 과립화한 다음, 활택제 등을 넣어 압축성형하거나, 상기 혼합물을 직접 압축성형할 수 있다. 또한, 상기 정제 형태의 건강기능식품은 필요에 따라 교미제 등을 함유할 수 있으며, 필요에 따라 적당한 제피제로 제피할 수도 있다.For example, the health functional food in the form of a tablet is granulated by a mixture with a complex extract, excipients, binders, disintegrants, and other additives in a conventional manner, and then a lubricant is added to compression molding, or the mixture is Direct compression molding is possible. In addition, the health functional food in the form of tablets may contain a mating agent, etc., if necessary, and may be coated with a suitable skinning agent if necessary.
캡슐 형태의 건강기능식품 중 경질캡슐제는 통상의 경질캡슐에 복합 추출물, 및 부형제 등의 첨가제와의 혼합물 또는 그의 입상물 또는 제피한 입상물을 충진하여 제조할 수 있으며, 연질캡슐제는 복합 추출물 및 부형제 등의 첨가제와의 혼합물을 젤라틴 등 캡슐기제에 충진하여 제조할 수 있다. 상기 연질캡슐제는 필요에 따라 글리세린 또는 소르비톨 등의 가소제, 착색제, 보존제 등을 함유할 수 있다.Among health functional foods in the form of capsules, hard capsules can be prepared by filling conventional hard capsules with a mixture of complex extracts and additives such as excipients, or their granules or coated granules, and soft capsules are complex extracts. And it can be prepared by filling a mixture with additives such as excipients in a capsule base such as gelatin. The soft capsule formulation may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, if necessary.
환 형태의 건강기능식품은 복합 추출물, 부형제, 결합제, 붕해제 등의 혼합물을 적당한 방법으로 성형하여 조제할 수 있으며, 필요에 따라 백당이나 다른 적당한 제피제로 제피를, 또는 전분, 탈크 또는 적당한 물질로 환의를 입힐 수도 있다.A health functional food in the form of a ring can be prepared by molding a mixture of complex extracts, excipients, binders, disintegrants, etc. in an appropriate way, and if necessary, the skin is coated with sucrose or other suitable skinning agent, or starch, talc, or a suitable material. You can also dress up.
과립형태의 건강기능식품은 복합 추출물, 부형제, 결합제, 붕해제 등의 혼합물을 적당한 방법으로 입상으로 제조할 수 있으며, 필요에 따라 착향제, 교미제 등을 함유할 수 있다. 과립형태의 건강기능식품은 12호 (1680 μm), 14호 (1410 μm) 및 45호 (350 μm) 체를 써서 다음 입도시험을 할 때에 12호체를 전량 통과하고 14호체에 남는 것이 전체량의 5.0 %이하이고 또 45호체를 통과하는 것은 전체량의 15.0 %이하일 수 있다.The health functional food in the form of granules may be prepared in granular form by an appropriate method of a mixture of complex extracts, excipients, binders, disintegrants, and the like, and may contain flavoring agents, flavoring agents, etc. as necessary. For health functional foods in granular form, use No. 12 (1680 μm), No. 14 (1410 μm), and No. 45 (350 μm) sieves to pass all the sieves in the next particle size test, and the remaining amount in No. 14 sieves 5.0% or less and passing through No. 45 may be less than 15.0% of the total amount.
상기 부형제, 결합제, 붕해제, 활택제, 교미제, 착향제 등에 대한 용어 정의는 당업계에 공지된 문헌에 기재된 것으로 그 기능 등이 동일 내지 유사한 것들을 포함한다 (대한약전 해설편, 문성사, 한국약학대학협의회, 제 5 개정판, p33-48, 1989).The term definitions for the excipients, binders, disintegrants, lubricants, flavoring agents, flavoring agents, etc. are described in documents known in the art and include those having the same or similar functions (Explanation of the Korean Pharmacopoeia, Moonseongsa, Korea) Association of Colleges of Pharmacy, 5th ed., p33-48, 1989).
상기 식품의 종류에는 특별한 제한이 없다. 본 발명의 추출물을 첨가할 수 있는 식품의 예로는 음료, 껌, 비타민 복합제, 드링크제 등이 있으며, 통상적인 의미에서의 건강기능식품을 모두 포함한다.There is no particular limitation on the type of the food. Examples of foods to which the extract of the present invention can be added include beverages, gums, vitamin complexes, drinks, and the like, and include all health functional foods in a conventional sense.
본 발명은 생지황, 현삼, 괄루인, 목단피, 치자, 인동등 및 별갑교 복합 추출물을 대상체에 투여하는 단계를 포함하는 당뇨병의 치료방법을 제공한다.The present invention provides a method for treating diabetes, comprising administering to a subject a complex extract of Saengjihwang, Hyeonsam, Gwaruin, Mokdanpi, Gardenia, Indongdung and Byeolgapgyo.
본 발명에 "생지황, 현삼, 괄루인, 목단피, 치자, 인동등 및 별갑교 복합 추출물", "당뇨병" 및 "투여" 등의 용어는 상기에서 설명한 바와 동일하다.In the present invention, terms such as "saengjihwang, ginseng, gwaruin, mokdanpi, gardenia, indongdeung and byeolgapgyo complex extract", "diabetes" and "administration" are the same as described above.
상기 대상체는 동물을 말하며, 전형적으로 본 발명의 생지황, 현삼, 괄루인, 목단피, 치자, 인동등 및 별갑교 복합 추출물을 이용한 치료로 유익한 효과를 나타낼 수 있는 포유동물일 수 있다. 이러한 대상체의 바람직한 예로 인간과 같은 영장류가 포함될 수 있다. 또한 이와 같은 대상체들에는 당뇨병의 증상을 갖거나 이와 같은 증상을 가질 위험이 있는 대상체들이 모두 포함될 수 있다.The subject refers to an animal, and typically may be a mammal that can exhibit beneficial effects by treatment using the complex extract of Saengjihwang, Hyeonsam, Gwaruin, Mokdanpi, Gardenia, Indongdeung and Byeolgapgyo of the present invention. Preferred examples of such subjects may include primates such as humans. Also, such subjects may include all subjects with or at risk of having symptoms of diabetes.
본 발명은 또한 당뇨병의 치료를 위한 약제의 제조에서 상기 생지황, 현삼, 괄루인, 목단피, 치자, 인동등 및 별갑교 복합 추출물의 용도를 제공한다. The present invention also provides the use of the complex extract of Saengjihwang, Hyeonsam, Gwaruin, Mokdanpi, Gardenia, Indongdung and Byeolgapgyo in the manufacture of a medicament for the treatment of diabetes.
본 발명은 또한 당뇨병의 치료에 사용하기 위한 상기 생지황, 현삼, 괄루인, 목단피, 치자, 인동등 및 별갑교 복합 추출물을 포함하는 조성물을 제공한다. The present invention also provides a composition comprising the extract of Saengjihwang, Hyeonsam, Gwaruin, Mokdanpi, Gardenia, Indongdung and Byeolgapgyo complex extract for use in the treatment of diabetes.
본 발명은 또한 당뇨병의 치료를 위한 상기 생지황, 현삼, 괄루인, 목단피, 치자, 인동등 및 별갑교 복합 추출물의 용도를 제공한다. The present invention also provides the use of the complex extract of Saengjihwang, Hyeonsam, Gwaruin, Mokdanpi, Gardenia, Indongdung and Byeolgapgyo for the treatment of diabetes.
본 발명에 따른 생지황, 현삼, 괄루인, 목단피, 치자, 인동등 및 별갑교 복합 추출물은 혈중 인슐린 농도를 크게 낮추고, 혈당 및 요당을 감소시키며 당화혈색소를 개선하며 케톤뇨의 수치를 안정화 시킴으로써 당뇨병에 대해 우수한 효과를 나타낸다. 이에 따라, 약학 조성물 또는 건강기능식품으로써 유용하게 사용될 수 있다. The complex extract of Saengjihwang, Hyeonsam, Gwaruin, Mokdanpi, Gardenia, Indongdung and Byeolgapgyo according to the present invention significantly lowers the blood insulin concentration, reduces blood sugar and urine sugar, improves glycated hemoglobin, and stabilizes the level of ketonuria for diabetes. It shows an excellent effect. Accordingly, it can be usefully used as a pharmaceutical composition or health functional food.
이하, 본 발명을 실시예를 통하여 더욱 상세히 설명한다. 그러나 이들 실시예 및 시험예는 본 발명을 예시하기 위한 것으로, 본 발명의 범위가 이들 실시예 및 시험예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples. However, these Examples and Test Examples are for illustrating the present invention, and the scope of the present invention is not limited to these Examples and Test Examples.
실시예 1. 복합 추출물의 제조 Example 1. Preparation of complex extract
모든 한약 재료의 경우 경동 시장의 한약 판매처를 통해 구매한 것을 사용하였다. 생지황 200g, 현삼 180g, 괄루인 140g, 목단피 100g, 치자 75g, 인동등 75g, 별갑교 30g 을 8,000ml 물에 넣고 80~100℃ 약탕기(무압력 또는 압력)에 넣고, 2~3시간 중탕하였다. 그리고 나서, 중탕 후 각각 120ml 씩 팩에 담아서 환자가 복용을 편히 할 수 있도록 포장하였다. In the case of all herbal medicine materials, those purchased through an herbal medicine vendor in Gyeongdong Market were used. 200 g of raw ginseng, 180 g of ginseng, 140 g of ginseng, 100 g of mulberry skin, 75 g of gardenia, 75 g of ginseng root, and 30 g of byeolgap bridge were put in 8,000 ml of water, put in a water heater (no pressure or pressure) at 80-100 ° C, and boiled for 2-3 hours. Then, after the bath, 120ml each was packed in a pack so that the patient could take it conveniently.
실시예 2. 복합 추출물들의 제조 Example 2. Preparation of complex extracts
상기 실시예 1의 복합 추출물의 성분에 추가하여 石膏(석고), 牡蠣(모려), 荊芥(형개) 및 防風(방풍)로 이루어진 군으로부터 선택되는 어느 하나 이상을 40 g 씩 더 추가하여, 10,000ml 물에 넣고 80~100℃ 약탕기(무압력 또는 압력)에 넣고, 2~3시간 중탕하였다. 이들 추가 성분들은 환자의 한의학적 상태를 고려하여, 1 이상 추가될 수 있는 성분들로써 당뇨 개선에 추가의 시너지 효과를 나타낼 수 있는 성분들에 해당한다. In addition to the components of the complex extract of Example 1, 40 g of any one or more selected from the group consisting of stone (gypsum), 牡蠣 (moryeo), Put it in water and put it in a water heater (no pressure or pressure) at 80-100° C., and boil it for 2-3 hours. These additional ingredients are ingredients that can be added to one or more in consideration of the patient's oriental medical condition, and correspond to ingredients that can exhibit an additional synergistic effect in improving diabetes.
중탕 후 각각 120ml 씩 팩에 담아서 환자가 복용을 편히 할 수 있도록 포장하였다.After the bath, 120ml each was packed in a pack so that the patient could take it conveniently.
실시예 3. 복합 추출물들의 제조 Example 3. Preparation of complex extracts
상기 실시예 2의 복합 추출물 성분에 추가로 羌活(강활) 獨活(독활) 前胡(전호) 지골피(地骨皮) 및 木通(목통)으로 이루어진 군으로부터 선택되는 어느 하나 이상을 40 g 씩 더 추가하여, 10,000ml 물에 넣고 80~100℃ 약탕기(무압력 또는 압력)에 넣고, 2~3시간 중탕하였다. 이들 추가 성분들은 환자의 한의학적 상태를 고려하여, 1 이상 추가될 수 있는 성분들로써 당뇨 개선에 추가의 시너지 효과를 나타낼 수 있는 성분들에 해당한다.In addition to the complex extract component of Example 2, 40 g each of at least one selected from the group consisting of In addition, it was put in 10,000ml water, put in a water heater (no pressure or pressure) at 80-100°C, and bathed for 2-3 hours. These additional ingredients are ingredients that can be added to one or more in consideration of the patient's oriental medical condition, and correspond to ingredients that can exhibit an additional synergistic effect in improving diabetes.
중탕 후 각각 120ml 씩 팩에 담아서 환자가 복용을 편히 할 수 있도록 포장하였다.After the bath, 120ml each was packed in a pack so that the patient could take it conveniently.
실시예 4. 복합 추출물의 농축 추출물의 제조 Example 4. Preparation of concentrated extract of complex extract
상기 실시예 1 내지 3에서 중탕으로 제조된 한약 배합 추출물을 "저압 농축기"를 통해 압력을 낮추어 가열하여 60 ℃에서 물이 끓어 증발토록 하여 물을 줄어들어 1000 ml 수준일때 (기계에 따라 가동 시간은 다름, 평균 시간당 3리터 수분 증발) 까지 농축을 시켰다. 그리고 나서, 해당 농축액을 각각 20 ml 로 포장하여 환자가 복용을 편히 할 수 있도록 포장하였다.When the herbal medicine blend extract prepared in Examples 1 to 3 is heated by lowering the pressure through a "low pressure concentrator" to boil and evaporate water at 60 ° C. , was concentrated up to 3 liters of water evaporation per hour on average). Then, the concentrate was packaged in 20 ml each so that the patient could take it conveniently.
실시예 5. 당뇨 개선 효과의 확인 Example 5. Confirmation of diabetes improvement effect
당뇨 환자군에 대하여 상기 제조된 복합 추출물 또는 농축 추출물을 처방하여 이의 치료 효과를 확인하였다. To the diabetic patient group, the above-prepared complex extract or concentrated extract was prescribed to confirm its therapeutic effect.
구체적으로, 2018년 7월1일부터 2018년11월30일까지 등록된 환자들 대상으로 차트리뷰를 통해 후향적으로 연구를 수행하였다. Specifically, from July 1, 2018 to November 30, 2018, the study was conducted retrospectively through chart review for registered patients.
조건은 30 세 이상의 성인 남녀로 2형 당뇨병을 가지고 있으며, 위 실시예 1의 성분을 포함하는 복합 추출물의 농축 추출물을 3개월 이상 복용한 환자군의 변화를 확인하였다. As for the condition, adult men and women over 30 years of age and having type 2 diabetes, the changes in the patient group who took the concentrated extract of the complex extract containing the components of Example 1 above for 3 months or more were confirmed.
이러한 30세 이상의 성인 남녀 중 임신이나 수유 중인 여성은 임상 대상군에서 제외하였으며, 위 처방을 자의적으로 중단한 경우 도한 본 임상 대상군에서 제외하였다. Among these adult men and women over 30 years of age, pregnant or lactating women were excluded from the clinical target group, and those who arbitrarily stopped the above prescription were also excluded from this clinical target group.
위 실시예 1의 성분을 포함하는 복합 추출물의 농축 추출물을 90팩(20ml)씩 환자에게 제공하였으며, 식전, 식간, 식후 언제든 복용하도록 하였다. 주의사항으로는 가능한 10시나 11시에 취침을 취하도록 하고, 인스턴트 음식을 주의하도록 하였다. 90 packs (20ml) each of the concentrated extract of the complex extract containing the components of Example 1 above was provided to the patient, and was to be taken before meals, between meals, and at any time after meals. As a precaution, try to go to bed at 10 or 11 o'clock if possible, and be careful about instant food.
(1) 임상 대상군의 일반 특성 (1) General characteristics of clinical subjects
[표 1] 임상 대상군의 일반 특성 [Table 1] General characteristics of clinical subjects
SY: So-Yang, DM medication: patients on western medication for diabetes mellitus (DM). SY: So-Yang, DM medication: patients on western medication for diabetes mellitus (DM).
임상 대상군으로 총 위와 같은 5 명이 선정되었다. 남자 3명, 여자 2명이었으며, 모두 당뇨 질환을 진단받은 대상자였으며, 소양인의 체질을 가지는 환자들에 해당하였다. A total of 5 patients as above were selected as the clinical target group. There were 3 males and 2 females, all of whom were diagnosed with diabetic disease, and they corresponded to patients with the constitution of Soyangin.
(2) 임상 대상군의 과거력 및 병력 (2) History and medical history of the clinical target group
분석대상자 5명의 당뇨병 이환기간은 3개월부터 길게는 12년까지 있었으며, 당뇨 양약은 2명이 미복용 상태였고, 나머지는 복용 상태였다. The duration of diabetes mellitus of 5 subjects was from 3 months to as long as 12 years, and 2 patients were not taking diabetic medications, and the rest were taking them.
[표 2] 임상 대상군의 과거력 및 병력 [Table 2] History and medical history of clinical subjects
(3) 당화혈색소(HbA1c) 변화 (3) Changes in glycated hemoglobin (HbA1c)
본 발명에 따른 위 실시예 1의 성분을 포함하는 복합 추출물의 농축 추출물을 복용하고 나서 1개월 단위로 당화혈색소 변화를 확인하였다. After taking the concentrated extract of the complex extract containing the components of Example 1 according to the present invention, the change in glycated hemoglobin was confirmed in units of one month.
그 결과를 표 3에 나타내었다. The results are shown in Table 3.
[표 3] 당화혈색소 변화[Table 3] Changes in glycated hemoglobin
표 3에서 확인할 수 있는 바와 같이, 소양인 그룹에서 상당히 큰 당화혈색소 개선을 나타내었다. 구체적으로, 위 5명에 해당하는 소양인 그룹에서 시간 경과에 따라 당화혈색소 측면에서 상당한 개선 효과를 나타내었다. As can be seen in Table 3, a significant improvement in glycated hemoglobin was shown in the Soyangin group. Specifically, the Soyangin group, corresponding to the above five, showed a significant improvement effect in terms of glycated hemoglobin over time.
(4) 소변의 요당 변화 (4) changes in urine sugar
본 발명에 따른 위 실시예 1의 성분을 포함하는 복합 추출물의 농축 추출물을 복용하고 나서 1개월 단위로 당화혈색소 변화를 확인하였다. After taking the concentrated extract of the complex extract containing the components of Example 1 according to the present invention, the change in glycated hemoglobin was confirmed in units of one month.
그 결과를 표 4에 나타내었다. The results are shown in Table 4.
[표 4] 요당 변화 확인 [Table 4] Confirmation of changes in urine sugar
표 4에서 확인할 수 있는 바와 같이, 임상 대상군 5명 모두에서 요당이 크게 줄어 드는 결과를 나타내었다. As can be seen in Table 4, urine sugar significantly decreased in all 5 clinical subjects.
상기 표 3 및 표 4를 통해 확인할 수 있는 바와 같이, 본 발명에 다른 복합 추출물의 투여는 임상 대상군에서 당화혈색소 및 요당을 개선하여, 당뇨에 대한 치료 효과를 나타내었다. 이러한 결과는 특히 실제 환자군에서의 직접적 치료 효과를 확인하였다는 점에서 임상적으로 유의미한 결과를 나타낸다. As can be seen from Tables 3 and 4, administration of the complex extract according to the present invention improved glycated hemoglobin and urine sugar in the clinical subject group, thereby exhibiting a therapeutic effect on diabetes. These results indicate clinically significant results in that they confirmed the direct treatment effect in the actual patient group.
더욱이, 이러한 질환 치료는 환자에게 특별한 생활 관리 지도 없이 평상시 생활 그대로 진행과정중에 한약 투여만으로 이루어진 결과라는 측면에서, 한의사의 적극적 생활지도가 병행이 되면 더 좋은 결과를 이루어낼 수 있을 것이라 사료된다.Moreover, it is thought that better results can be achieved if the active life guidance of an oriental doctor is used in parallel with the treatment of these diseases in terms of the result of only administering herbal medicines during the course of normal life without any special life management guidance to the patient.
실시예 6. 당뇨 개선 효과의 확인을 위한 case study 결과 Example 6. Case study results for confirming the diabetes improvement effect
당뇨를 앓고 있는 개별 환자들에 대하여 본 발명에 따른 복합 추출물 처방에 따른 치료 효과를 개별적으로 확인하여, 그 결과를 아래와 같이 정리하였다. For individual patients suffering from diabetes, the therapeutic effect of the complex extract prescription according to the present invention was individually confirmed, and the results were summarized as follows.
(1) Case study 1 (KJS(남성/30) 증례일지)(1) Case study 1 (KJS (male/30) case log)
1. 주소증1. address card
口乾, 夜間頻尿, 體重減少(116Kg-> 99Kg; 2016년 여름에 발생) 口乾, 夜間頻尿, 体重減少 (116Kg -> 99Kg; occurred in the summer of 2016)
2. 과거력 : 특이사항 없음2. Past history: no specifics
3. 현병력3. Current military history
상기자는 만 30세의 건장한 체형(182㎝/99.4㎏)의 남환으로 직업은 화물기사이며 평상시 업무량이 과다하고 스트레스가 과다한 상태였다고 한다. 평상시 음식은 외식위주로 인스턴트 음식섭취가 많았고, 음주 횟수는 주6회였으나 최근 당뇨합병증이 걱정되어 주1회로 줄인 상황이었다. The person mentioned above is a 30-year-old male with a strong body type (182 cm / 99.4 kg) who is a freight driver by profession. The usual food was eating out, eating out a lot of instant food and drinking 6 times a week, but recently it was reduced to once a week due to concerns about diabetes complications.
2015년 12월 목디스크 수술하러 병원방문했을 때 당뇨병 진단받고 당뇨약은 3~4일 복용후 속이 불편하여 복용 중단하였고 이후 당뇨에 좋다는 식품을 섭취하였으며, 최근 한달전부터는 당컨트롤, 케이뉴트라를 복용하던중 4일전 공복혈당이 250mg/dl이 측정되고, 口乾과 頻尿가 1년이상 지속되어 2017년 4월 18일에 본 한의원에 내원하였다. When I visited the hospital for neck disc surgery in December 2015, I was diagnosed with diabetes, and after taking the diabetes medication for 3 to 4 days, I stopped taking it because of discomfort in my stomach. The fasting blood glucose level was 250 mg/dl 4 days ago, and the oral and nasal symptoms lasted more than 1 year, and on April 18, 2017, he visited this oriental clinic.
4 주요 검사소견4 Major findings
1) 2017년 4월 18일 본원 검사 1) April 18, 2017 Inspection at the hospital
혈압 : 132/90㎜Hg, 식후혈당 : 130㎎/㎗(식후 6시간40분), HbA1c : 9.0 % Blood pressure: 132/90mmHg, postprandial blood sugar: 130mg/dl (6 hours and 40 minutes after a meal), HbA1c: 9.0%
요당 양성(+) Urine sugar positive (+)
5. 초진소견5. First visit
1) 消化器系; 消化良好, 心下(+) 1) 消化器系;消化良好, heart lower(+)
2) 飮酒 : 1일/주, 소주 2병/회 ( 몇 달전까지 주 6회 정도 음주 ) 2) 飮酒: 1 day/week, 2 bottles/time of soju (drinking about 6 times a week until a few months ago)
3) 睡眠 : 화물기사이므로 불규칙한 수면시간, 수면양은 1일 5시간 3) 睡眠: I am a cargo driver, so I have irregular sleeping hours, and the amount of sleep is 5 hours a day.
入眠難, 수면중 소변 1~2회 보러간다. 入眠難, go to urinate 1-2 times during sleep.
4) 汗 : 전신에 땀 많이 흘림 4) 汗: Sweat a lot all over the body
5) 大便 : 2~3회/일 5) 大便: 2-3 times/day
6) 舌診 : 舌大, 質裂, 無苔 6) 舌診: 舌大, 質裂, no 苔
7) 脈診 : 沈滑, 84회/분 7) 脈診 : 沈滑, 84 times/min
8) 생활습관 : 화물기사로 근무하면서 업무량이 많고, 스트레스가 많다. 8) Lifestyle: Working as a freight driver, there is a lot of work and a lot of stress.
외식을 자주하였으나, 최근 집밥으로 먹으려고 노력중. I used to eat out often, but I've been trying to eat at home lately.
6 한약처방 및 생활관리6 Herbal medicine prescription and daily life management
6-1 한약 6-1 Herbal medicine
[표 5] 처방 한약 [Table 5] Prescription herbal medicine
6-2 생활관리 지도 6-2 Living management guidance
1) 수면; 11시 이내에 잠을 잘 것1) sleep; go to bed by 11 o'clock
뇌, 망막은 오직 포도당만을 에너지로 사용한다. 뇌와 망막의 에너지원인 당의 사용량을 줄여주기 위해서 양질의 수면습관이 중요하다는 판단에서 밤 11시 이전에 취침하도록 하였다. The brain and retina use only glucose for energy. In order to reduce the amount of sugar, which is an energy source for the brain and retina, it was decided to go to bed before 11 p.m. in the judgment that a good sleep habit is important.
2) 음식; 정제된 탄수화물인 인스턴트 식품들(빵, 라면, 탄산음료등) 삼가할 것. 일반 한식은 충분히 식사하되, 천천히 씹어서 드실 것.2) food; Avoid instant foods that are refined carbohydrates (bread, ramen, soda, etc.). In general, eat enough Korean food, but chew it slowly.
3) 운동; 근무여건상 운동은 어려운 상황이므로, 운전중 눈의 피로 회복을 위해 중간에 스트레칭을 하고, 2시간 운전에 15분 휴식을 꼭 갖도록 지도하였다.3) exercise; Because exercise was difficult due to working conditions, they were instructed to stretch in the middle to recover from eye fatigue while driving, and to take a 15-minute break after driving for 2 hours.
7 경과사항7 Progress
1) 5월 1일(치료경과 13일) - 몸무게 99.7㎏ 1) May 1 (13 days after treatment) - Weight 99.7 kg
혈당 121㎎/㎗( 식후 5시간 40분), 요당(-) Blood sugar 121㎎/㎗ (5 hours 40 minutes after meals), urine sugar (-)
소변횟수가 줄었음. Reduced urination.
2) 5월 24일(치료경과 37일) - 몸무게 99.5㎏ 2) May 24 (37 days after treatment) - Weight 99.5 kg
혈당 126㎎/㎗(식후5시간) 요당(-) Blood sugar 126mg/dl (5 hours after meals) Urine sugar (-)
수면중 중간에 깨지 않는다. Do not wake up in the middle of sleep
3) 6월 14일(치료경과 1개월 26일) - 몸무게 99.5㎏ 3) June 14 (1 month and 26 days after treatment) - Weight 99.5 kg
혈당 125㎎/㎗(식후3시간30분) 요당(-) Blood sugar 125㎎/㎗ (3 hours 30 minutes after meals) Urine sugar (-)
소변횟수가 줄어서 편하다고 하였고 불편증상이 없다고 하였다. They said that they were comfortable because the frequency of urination was reduced and that there were no discomfort symptoms.
움주는 1주일에 1회 과음한다고 하였다. 운동은 주3~4회 배드민턴을 하고 있음 It was said that Umju drinks excessively once a week. Exercise: I play badminton 3-4 times a week.
4) 6월 28일(치료경과 2개월 10일) - 몸무게 96.9㎏ 4) June 28 (2 months and 10 days after treatment) - Weight 96.9 kg
혈당 102㎎/㎗(식후5시간40분) HbA1c 7.3%, 요당(-) Blood sugar 102 mg/dl (5 hours 40 minutes after meals) HbA1c 7.3%, urine sugar (-)
口乾 없고, 頻尿 소실되었고, 잠을 푹 자고 있다. There is no 口乾, 頻尿 has disappeared, and he is sleeping soundly.
야식은 1주일 1~2회, 음주는 1회/1주일, 운동 3~4회/1주일 Late-night meals 1-2 times a week, drinking alcohol once/week, exercise 3-4 times/week
5) 7월 19일(치료경과 3개월) - 몸무게 97.9㎏ 5) July 19th (3 months after treatment) - Weight 97.9kg
혈당 121㎎/㎗(식후5시간 30분), HbA1c 6.2%, 요당(-) Blood sugar 121mg/dl (5 hours 30 minutes after meals), HbA1c 6.2%, urine sugar (-)
운동은 못했고, 음주 2회/1주(소주 3~4병/1회) I couldn't exercise, I drank 2 times/week (3~4 bottles of soju/time)
수면을 1일 5시간 상태여서 피로감이 있다고 함. He said he was tired because he slept 5 hours a day.
6) 7월 19일 ~ 9월 26일 (전화상담) 6) July 19th ~ September 26th (phone consultation)
화물 운전 지역이 변해서 내원이 어려워서 전화 상담후 처방함 It was difficult to come to the hospital due to the change in the cargo operation area, so I prescribed it after consulting by phone.
식후혈당 110mg/dl 정도 나온다고 하며, 특이사항 없이 건강은 잘 유지하고 있음 It is said that postprandial blood sugar is about 110mg/dl, and he is in good health
[표 6] 환자의 혈당, 요당 및 당화혈색소 변화 [Table 6] Changes in blood sugar, urine sugar, and glycated hemoglobin in patients
상기 표를 통해 확인할 수 있는 바와 같이, 약물 처방 후 요당은 없어졌고, 혈당 및 당화 혈색소가 크게 개선됨을 확인할 수 있다. As can be seen from the above table, it can be confirmed that after drug prescription, urine sugar disappeared and blood sugar and glycated hemoglobin were significantly improved.
(2) Case study 2 (KCS(남성/51) 증례일지(2) Case study 2 (KCS (male/51) case log)
1 주소증1 address card
渴症, 夜間頻尿, 疲勞, 體重減少, 피부 가려움, 渴症, 夜間頻尿, 疲勞, skin itching,
2 과거력2 past history
4년전부터 혈압약과 아스피린 복용중, 3개월전부터 콜레스테롤약 복용중.I have been taking blood pressure medicine and aspirin since 4 years ago, and cholesterol medicine since 3 months ago.
3 현병력3 current military
2013년 11월 16일 口乾, 渴症, 體重減少, 다리저림, 夜間頻尿로 인한 수면장애의 증상으로 내원하였으며, 증상은 내원 45일전에 발생하였고 치료를 위해 동네 한의원으로 처음 방문하여 15일간 한약투여 및 침치료 받고난 후 피로감은 개선되었으나 당뇨병을 적극적으로 한방 치료하고자 추가 치료를 받고자 하였다. On November 16, 2013, he visited the hospital with symptoms of sleep disturbance due to 口乾, 渴症, 体重減少, numbness in the legs, and 夜間頻尿. After receiving herbal medicine and acupuncture treatment, fatigue was improved, but he wanted to receive additional treatment for active oriental treatment of diabetes.
2013년 11월 16일 초진 내원시 口乾, 다리저림, 疲勞, 피부 가려움 증상의 불편을 많이 호소하였다.On November 16, 2013, when he visited the hospital for the first time, he complained of many complaints of discomfort in the mouth, numbness in the legs, skin irritation, and itching of the skin.
4. 주요검사소견4. Major inspection findings
1) 2013년 11월 16일 본원 검사1) November 16, 2013 Inspection at the hospital
혈당 : 499㎎/㎗(식후3시간 50분 ), HbA1c : 12 % 요당 양성(++++) Blood sugar: 499mg/dl (3 hours 50 minutes after meals), HbA1c: 12% urine sugar positive (++++)
5 초진소견5 First visit
1) 消化器系1) 消化器系
消化不良(+), 속쓰림(-), 心下(+), 허기짐은 없다. There is no 消化不良(+), heartburn(-), 心下(+), no hunger.
음식 빨리 먹는편, 3끼 식사 규칙적으로 섭취. Eat fast, eat 3 meals a day regularly.
2) 飮酒 : 1달 2~3회(1회 소주2병), 3년전까지는 음주가 많았다. 2) 飮酒: 2~3 times a month (2 bottles of soju at a time), until 3 years ago, I drank a lot.
3) 睡眠 : 불규칙하나 최근 10시 ~5시 3) 睡眠 : Irregular but the last 10 ~ 5 o'clock
4) 汗 : 날씨가 더우면 많이 흘리고 특히 머리에서 많이 흘린다. 4) 汗 : When the weather is hot, it sheds a lot, especially from the head.
5) 大便 : 1회/일, 불편함 없음 5) 大便: 1 time/day, no discomfort
6) 舌診 : 舌大, 質燥, 無苔 6) 舌診: 舌大, 質燥, no 苔
7) 脈診 : 沈滑數, 81회/분 7) 脈診 : 沈滑數, 81 times/min
8) 생활습관 : 소속 단체에서 간부직이며, 45일전부터 신경 쓸 일이 많았다. 8) Lifestyle: I am an executive at my organization, and I had a lot of things to worry about since 45 days ago.
6. 한약처방 및 생활관리6. Herbal medicine prescription and daily life management
6-1 생활관리 6-1 Life management
1) 수면; 11시 이내에 잠을 잘 것 1) sleep; go to bed by 11 o'clock
뇌, 망막은 오직 포도당만을 에너지로 사용한다. 뇌와 망막의 에너지원인 당의 사용량을 줄여주기 위해서 양질의 수면습관이 중요하다는 판단에서 밤 11시 이전에 취침하도록 하였다. The brain and retina use only glucose for energy. In order to reduce the amount of sugar, which is an energy source for the brain and retina, it was decided to go to bed before 11 p.m. in the judgment that a good sleep habit is important.
2) 음식; 정제된 탄수화물인 인스턴트 식품들(빵, 라면, 탄산음료등) 삼갈 것. 일반 한식은 충분히 식사하되, 천천히 씹어서 드실 것. 2) food; Avoid instant foods that are refined carbohydrates (bread, ramen, soda, etc.). In general, eat enough Korean food, but chew it slowly.
3) 운동; 1주일 1회 등산(왕복 2시간 코스) 정도의 강도로 할 것. 3) exercise; Climb once a week (2 hour round trip course) with an intensity of about the same.
6-2 한약처방 6-2 Herbal medicine prescription
[표 7] 처방 한약 [Table 7] Prescription herbal medicine
7. 경과사항7. Progress
1) 2013년 12월 7일 - 체중 63Kg 1) December 7, 2013 - Weight 63Kg
무기력감, 피로감, 부종, 다리 저림 소실 Loss of lethargy, fatigue, edema, numbness in the legs
2) 2014년 1월 4일 - 체중 67.2Kg 2) January 4, 2014 - Weight 67.2Kg
빠졌던 체중이 조금 증가했음. 반신욕 매일 30~40분 정도 하고 있으며 수면은 12 시 넘어서 잔다.(절 행사 준비 때문에 늦게 잔다) The weight I lost has increased slightly. I take a half-bath for about 30-40 minutes every day, and I go to bed after 12 o'clock.
3) 2월 4일 - 체중 66Kg 3) February 4th - Weight 66Kg
점심 식사후에 나른하고 피곤함이 있다. 컨디션은 좋다. I feel drowsy and tired after lunch. Condition is good.
수면(10시 ~5시 30분, 새벽3시정도 한번씩 깬다), 舌苔薄 脈滑(12회/10초) Sleep (10:30-5:30, waking up at around 3 am)
4) 3월 21일 - 체중 67Kg 4) March 21st - Weight 67Kg
혈압약, 콜레스테롤약, 아스피린 모두 복용 중단한지 1달 경과됨 It has been 1 month since I stopped taking blood pressure medicine, cholesterol medicine, and aspirin.
혈압 121/86, 혈당 110mg/dl(식후2시간), HbA1c 6.5% Blood pressure 121/86, blood sugar 110mg/dl (2 hours after meals), HbA1c 6.5%
아침 기상시에 주먹쥘 때 뻑뻑함. 기상시 몸이 붓는 느낌이라고 호소 Stiffness when clenching fists when waking up in the morning. Complaining that the body feels swollen when waking up
5) 4월 18일 - 체중 67 Kg 5) April 18 - Weight 67 Kg
수면시간 다시 늦어짐. 음주 2주간 3회 했음 Sleeping late again. Drinking 3 times in 2 weeks
脈沈緩 손가락 부종 약간 있음. 식사량을 2/3으로 줄였음(1주일전부터) 脈沈緩 There is some swelling in the fingers. Reduced the amount of food by 2/3 (from 1 week ago)
6) 6월 2일 - 체중 68.2 Kg 6) June 2nd - Weight 68.2 Kg
주말 등산을 무리하게 해서 피곤함. 음주 안하고 복용하는 양약 없음 Tired of overdoing hiking on the weekend. No drinking and no western medicine
부종은 더 이상 호소하지 않음. Edema no longer complains.
7) 8월 30일 - 체중 68.1Kg 7) August 30th - Weight 68.1Kg
8월 20일부터 탕약을 환약으로 처방 변경하여 컨디션 유지 및 관리로 전환 From August 20, changing the prescription from decoction to pills to maintain and manage physical condition
환약은 몸이 피곤할 때 1일 3회(25환/1회) 복용하였음. The pill was taken 3 times a day (25 pills/1 time) when the body was tired.
8) 10월 18일 - 체중 67.5Kg 8) October 18 - Weight 67.5Kg
일이 많이 바빠서 피로하다, 티벳 버섯 복용하다가 중단했음 Tired of being busy with work, I stopped taking Tibetan mushrooms
9) 2015년 4월 4일 - 체중 67.5Kg 9) April 4, 2015 - Weight 67.5Kg
환약을 1일 아침 저녁 2회 복용중(1회 20환), 가정사가 많았다. I was taking the pill twice a day in the morning and evening (20 pills at a time), and there were many family problems.
10) 9월 19일 - 체중 67.5Kg 10) September 19th - Weight 67.5Kg
식도염에 관련된 양약을 3일전부터 먹고 얼굴 홍조, 눈충혈 있었다. I ate Western medicine for esophagitis 3 days ago, and there was redness in the face and red eyes.
HbA1c 7.3% HbA1c 7.3%
11)2016년 4월 13일 - 체중 67.5Kg 11) April 13, 2016 - Weight 67.5Kg
일상일이 바쁘고 스트레스가 많다고 함. 입안이 달달한 느낌, 가슴통증 호소 Daily life is busy and stressful. A feeling of sweetness in the mouth, complaints of chest pain
혈압 157/98 ( 혈압약 중단한지 2년 경과) Blood pressure 157/98 (2 years after stopping blood pressure medication)
대변 최근 묽어지고, 식도염 증상은 여전함, 舌齒痕 발생. 음식 섭취후 소화는 양호 The stool has recently become thin, and the symptoms of esophagitis are still there, and bloating occurs. Good digestion after eating
탕약 재투여를 권유하여 한약 형방도적산 투여함 The herbal medicine Hyeongbangdojeoksan was administered by recommending the re-administration of the decoction.
12) 6월 24일 - 체중 67.7Kg 12) June 24 - Weight 67.7Kg
혈압 130/80, 식도염 증상 없음. 입안 달달한 느낌 없음 Blood pressure 130/80, no symptoms of esophagitis. No sweet taste in the mouth
HbA1c 6.6% HbA1c 6.6%
13) 7월 18일 - 체중 68 Kg 13) July 18 - Weight 68 Kg
혈압 160/95, HbA1c 6.9%, 최근 2주간 장거리 이동으로 무리했다고 함 Blood pressure 160/95, HbA1c 6.9%
탕약복용이 어렵다고, 본인이 생활관리를 하면서 지내겠다고 하면서 He said that it was difficult to take decoctions and that he would live by managing his own life.
형방지황탕 환약을 복용하기를 원함. He wants to take Hyeongbang-hwang-tang pills.
12)2017년 2월 10일 - 체중 67.5Kg 12) February 10, 2017 - Weight 67.5Kg
장거리 운전 많이하고 손자 돌보느라 수면도 불편했음 I did a lot of long-distance driving and had trouble sleeping because I was taking care of my grandchildren.
양약 및 건강기능 식품 복용하는 것 없음. HbA1c 6.3% No Western medicines and health functional foods are taken. HbA1c 6.3%
[표 8] 환자의 혈당, 요당 및 당화혈색소 변화 [Table 8] Changes in blood sugar, urine sugar and glycated hemoglobin in patients
고혈당으로 당뇨병 진단이후 양약 복용없이 한약으로 적극적으로 치료하여 초진시(2013년 11월 26일) 혈당 499mg/dl HbA1c 12% 수치가 7개월 뒤(2014년 6월 2일) 혈당 95mg/dl HbA1c 5.9% 확인되었다. 또한, 2017년 2월 10일 현재에도 혈당 145mg/dl HbA1c 6.3% 으로 확인되어 유지 중에 있다. After diagnosis of diabetes due to hyperglycemia, active treatment with herbal medicines without taking Western medicines. At the first visit (November 26, 2013), the blood sugar level of 499mg/dl HbA1c 12% after 7 months (June 2, 2014), the blood sugar 95mg/dl HbA1c 5.9 % confirmed. In addition, as of February 10, 2017, the blood glucose level was confirmed to be 145 mg/dl HbA1c 6.3% and is being maintained.
(3) Case study 3 (PTY(M/57) 증례일지(3) Case study 3 (PTY(M/57) case log
1. 주소증1. address card
口乾, 疲勞感, 2형 당뇨병, 소양인 消渴 口乾, 疲勞感, type 2 diabetes, soyangin 消渴
2. 과거력 : 2016년 11월 30일 삼성의료원 심근경색 관상동맥 우회 수술 시행. 2. History: On November 30, 2016, Samsung Medical Center performed coronary artery bypass surgery for myocardial infarction.
3. 현병력3. Current military history
상기자는 만 57세의 일반 체형(170㎝/78.1㎏)의 남환으로 직업은 교장선생님이다. The person mentioned above is a 57-year-old male with a normal body type (170 cm/78.1 kg) and his occupation is a principal.
평소에 음주가 많고 직장검진 결과 간수치 높다는 설명을 들었으며, 업무 관련 스트레스가 많았다고 한다. 2016년 11월 30일 컨디션 이상으로 지역 병원 내원하여 심근경색 진단후 삼성의료원으로 전원하여 관상동맥 우회 수술을 받고 양약 복용중이었다. I was told that I usually drink a lot, and as a result of the workplace examination, I had high liver levels, and that there was a lot of work-related stress. On November 30, 2016, he visited a local hospital due to an abnormal condition and was diagnosed with myocardial infarction.
2017년 5월 10일 병원에서 검사를 받고 혈당 276mg/dl, HbA1c 10.0% 결과가 나온 이후 당뇨진단과 함께 당뇨약(다이아벡스, 포시가정)을 처방 받고 복용하였다.On May 10, 2017, after being tested at the hospital and the results of blood sugar 276mg/dl and HbA1c 10.0% came out, he was diagnosed with diabetes and was prescribed diabetes medication (Diabex, Posigagat).
갑자기 늘어나는 양약과 함께 당뇨합병증에 대한 걱정과 피로감이 지속되어, 당뇨약을 복용하던중 한방 치료를 하고자 2017년 5월 27일에 내원하였다. With the sudden increase in Western medicine, worries about diabetes complications and fatigue persisted, so I came to the hospital on May 27, 2017 for herbal treatment while taking diabetes medicine.
4 주요 검사소견4 Major findings
1) 2017년 5월 10일 (포항 00병원 검사) 1) May 10, 2017 (Inspection at Pohang 00 Hospital)
혈당 : 270㎎/㎗ , HbA1c : 10.0 % Blood sugar: 270㎎/㎗ , HbA1c: 10.0%
2) 2017년 5월 27일 (본 한의원 검사) 2) May 27, 2017 (Prosecutor at this oriental clinic)
당뇨약(다이아벡스500mg 1알, 포시가10mg 1알 ) 1회/1일, 15일간 복용중 Diabetes drug (diabex 500mg 1 tablet, Forsiga 10mg 1 tablet) 1 time/day, 15 days taking
혈당 109 mg/dl (식후 5시간 30분), HbA1c : 9.3 %, 요당(++) Blood sugar 109 mg/dl (5 hours 30 minutes after meals), HbA1c: 9.3 %, urine sugar (++)
혈압 129/83 mmHg Blood pressure 129/83 mmHg
5. 초진소견5. First visit
1) 消化器系; 消化良好, 心下(+) 1) 消化器系;消化良好, heart lower(+)
2) 飮酒 : 심장 수술 전까지는 음주가 많았으나, 이후로는 음주 거의 안함 2) 飮酒: I drank a lot before heart surgery, but I rarely drink after that.
3) 睡眠 : 밤 12시 ~ 새벽5시, 수면양이 적다. 3) 睡眠: 12 pm to 5 am, the amount of sleep is small.
4) 汗 : 多, 더위를 많이 탄다 4) 汗 : 多, burns a lot of heat
5) 大便 : 1회/일, 불편 없음 5) 大便: 1 time/day, no inconvenience
6) 舌診 : 舌質裂甚, 白苔有, 입술색이 검다. 6) 舌診: 舌質裂甚, 白苔有, lip color is black.
7) 脈診 : 沈滑, 66회/분 7) 脈診 : 沈滑, 66 times/min
8) 생활습관 : 심장 수술하기전에 스트레스 많았고, 음주가 많았다. 8) Lifestyle: Before the heart surgery, there was a lot of stress and a lot of drinking.
최근 아침 식사는 계란 후라이+ 야채 쥬스 섭취중 Recently, for breakfast, I am eating fried egg + vegetable juice.
6 한약처방 및 생활관리6 Herbal medicine prescription and daily life management
6-1 한약 6-1 Herbal medicine
[표 9] 처방 한약 [Table 9] Prescription herbal medicine
6-2 생활관리 지도6-2 Living management guidance
1) 수면; 11시 이내에 잠을 잘 것1) sleep; go to bed by 11 o'clock
뇌, 망막은 오직 포도당만을 에너지로 사용한다. 뇌와 망막의 에너지원인 당의 사용량을 줄여주기 위해서 양질의 수면습관이 중요하다는 판단에서 밤 11시 이전에 취침하도록 하였다. The brain and retina use only glucose for energy. In order to reduce the amount of sugar, which is an energy source for the brain and retina, it was decided to go to bed before 11 p.m. in the judgment that a good sleep habit is important.
2) 음식; 정제된 탄수화물인 인스턴트 식품들(빵, 라면, 탄산음료등) 삼가할 것.2) food; Avoid instant foods that are refined carbohydrates (bread, ramen, soda, etc.).
일반 한식은 충분히 식사하되, 천천히 씹어서 드실 것. In general, eat enough Korean food, but chew it slowly.
3) 운동; 격렬한 운동보다 심신을 이완시켜줄 수 있는 산책을 지도. 3) exercise; Teach a walk that can relax the mind and body rather than strenuous exercise.
7 경과사항7 Progress
1) 6월 24일(치료경과 27일) - 몸무게 77.5㎏ 1) June 24 (27 days after treatment) - Weight 77.5 kg
혈당 115㎎/㎗( 식후 6시간 30분), 요당(-) 혈압 128/82 mmHg Blood sugar 115㎎/㎗ (6 hours 30 minutes after meals), urine sugar (-) blood pressure 128/82 mmHg
당뇨약 다이아벡스 500mg 1알 복용중 (한약복용후 포시가 복용 중단) Diabetes drug Diabex 500mg taking 1 tablet (stop taking Posiga after taking herbal medicine)
11시 이내에 잠을 자려고 노력중, 검붉은 입술색이 호전중. Trying to sleep within 11 o'clock, the dark red lip color is improving.
( 6월 20일 보건소 검사 결과지 ) HbA1c 7.6% (June 20 public health center test result) HbA1c 7.6%
2) 7월 22일(치료경과 1달 25일) - 몸무게 77.5㎏ 2) July 22 (1 month and 25 days after treatment) - Weight 77.5 kg
혈당 91㎎/㎗(식후3시간40분) 요당(+), HbA1c 7.3% Blood sugar 91mg/dl (3 hours 40 minutes after meals) Urine sugar (+), HbA1c 7.3%
당뇨약 다이아벡스 500mg 1알 저녁에 복용중(지난주 2회 복용 안함) Diabetes drug Diabex 500mg 1 tablet in the evening (I did not take it twice last week)
몸이 가벼워진듯하고 좋다고 표현함. 불편사항이 없음 He said that his body felt lighter and that he felt good. no inconvenience
3) 8월 19일(치료경과 2개월 22일) - 몸무게 77.1㎏ 3) August 19th (2 months and 22 days after treatment) - Weight 77.1kg
혈당 105㎎/㎗(식후5시간20분) 요당(-) 혈압 124/80 mmHg Blood sugar 105mg/dl (5 hours 20 minutes after meals) Urine sugar (-) Blood pressure 124/80 mmHg
당뇨약 복용 안함 (7월 22일부터는 다이아벡스 복용 중단) Do not take diabetes medication (Stop taking Diabex from July 22)
불편함은 없으나, 소변에 거품이 많은 것이 신경쓰인다고 함. There is no discomfort, but it is said that he is concerned about a lot of foam in the urine.
4) 9월 16일(치료경과 3개월 19일) - 몸무게 76.4㎏ 4) September 16 (3 months and 19 days after treatment) - Weight 76.4 kg
혈당 111㎎/㎗(식후6시간) 요당(-) HbA1c 6.8%, Blood sugar 111mg/dl (6 hours after a meal) Urine sugar (-) HbA1c 6.8%,
수면중 새벽2~3시쯤 개서 소변보러 감, 소변 거품이 많음 I wake up around 2-3 am during sleep and go to urinate, there is a lot of foam in the urine
아침 저녁으로 1시간 20분식 산책함. 1 hour and 20 minute walks in the morning and evening.
( 포항00 병원 9월 13일 검사 결과지) HbA1c 7.0% 혈당 129 ㎎/㎗ (Pohang 00 Hospital September 13th test result) HbA1c 7.0% Blood sugar 129 ㎎/㎗
5) 11월 18일(치료경과 5개월 21일) - 몸무게 77.2㎏ 5) November 18th (5 months and 21 days after treatment) - Weight 77.2kg
혈당 105㎎/㎗(식후5시간 20분), 요당(-) HbA1c 7.0%, 혈압 115/75 mmHg Blood sugar 105 mg/dl (5 hours 20 minutes after meals), urine sugar (-) HbA1c 7.0%, blood pressure 115/75 mmHg
블랙커피 매일 1~2잔 마시고 있음. 11월에 음주 1회. 매일 산책중 I drink 1-2 cups of black coffee every day. 1 drink in November. walking every day
6) 2018년 1월 29일 (치료경과 8개월) - 몸무게 78.4 Kg 6) January 29, 2018 (8 months after treatment) - Weight 78.4 Kg
혈당 125㎎/㎗(식후2시간), 요당(-) HbA1c 6.6%, Blood sugar 125 mg/dl (2 hours after meals), urine sugar (-) HbA1c 6.6%,
컨디션 좋고, 입술색은 현저히 검은색이 없이 붉어졌음. 백태가 많이 없어짐. The condition is good, and the lip color is red without noticeably black. A lot of white spots are gone.
[표 10] 환자의 혈당, 요당 및 당화혈색소 변화[Table 10] Changes in blood sugar, urine sugar and glycated hemoglobin in patients
상기 확인할 수 있는 바와 같이, 환자의 요당, 혈당 및 당화혈색소 모두 우수한 개선 효과를 나타내었다. As can be seen above, the patient's urine sugar, blood sugar, and glycated hemoglobin showed excellent improvement effects.
(4) Case study 4 LDS(M/45) 증례일지(4) Case study 4 LDS (M/45) case log
1. 주소증1. address card
渴症, 夜間頻尿, 心煩, 疲勞, 體重減少 渴症, 夜間頻尿, 心煩, 疲勞,
2. 과거력 : 2011년 백내장 수술(오른쪽)2. History: Cataract surgery in 2011 (right)
3. 현병력3. Current military history
상기자는 만 45세의 건장한 체형(180㎝/83.7㎏)의 남환으로 2016년 5~6월 체중 감소(88㎏ →㎏), 갈증, 피로감 발생하여 6월 21일 오전 서울모의원에서 혈액검사 통해 당뇨병 진단 받았다. 해당의원에서 혈당이 매우 높아 입원 및 인슐린펌프 시술 권유받았으나 한의학적인 치료를 받기위해 본원에 내원하였다. 내원당시 심한 渴症, 夜間頻尿, 體重減少, 피로감과 함께 소변검사상의 케톤(++)과 단백뇨(++) 모두 양성으로 나타났다. 上消, 中消 관련 증상 확인되고, 최근 두 달간 야근하며 스트레스 심하게 받았고 단백뇨가 나오는 상황이었다. The above person is a 45-year-old male with a strong body type (180 cm / 83.7 kg), and in May-June 2016, weight loss (88 kg → kg), thirst, and fatigue occurred. diagnosed He was recommended for hospitalization and insulin pump surgery because his blood sugar was very high at the hospital, but he came to the hospital to receive oriental medical treatment. At the time of admission, ketones (++) and proteinuria (++) were both positive, along with severe fatigue, fatigue, and fatigue. Symptoms related to upper and middle arms were confirmed, and over the past two months, he had been working overtime and under a lot of stress, and he had proteinuria.
4 주요 검사소견4 Major findings
1) 2016년 6월 21일 본원 검사 1) Inspection at the hospital on June 21, 2016
혈압 : 148/105㎜Hg, 식후혈당 : 322㎎/㎗(식후 5시간32분), HbA1c : 11.3 % Blood pressure: 148/105mmHg, postprandial blood sugar: 322mg/dl (5 hours and 32 minutes after meals), HbA1c: 11.3%
요당 양성(++), 케톤양성(++), 단백뇨 양성(++) Urine sugar positive (++), ketone positive (++), proteinuria positive (++)
5. 초진소견5. First visit
1) 消化器系 1) 消化器系
消化不良(+), 속쓰림(-), 心下(+) 消化不良(+), heartburn(-), 心下(+)
음식 빨리 먹는편, 아침;빵, 점심;식당, 저녁;자택에서 늦게 먹는편 Eat food early, breakfast; bread, lunch; restaurant, dinner; eat late at home
2) 飮酒 : 1일/주, 소주 1병/회 2) 飮酒: 1 day/week, 1 bottle of soju/time
3) 睡眠 : 밤12시 ~ 6시(새벽2~3시 소변 보기위해 깸) 3) 睡眠: 12 pm to 6 pm (Wake up to urinate 2 to 3 am)
4) 汗 : 평소 땀 많이 흘림 4) 汗 : I usually sweat a lot.
5) 大便 : 1회/일, 불편함 없음 5) 大便: 1 time/day, no discomfort
6) 舌診 : 舌大, 質淡紅微燥, 無苔 6) 舌診: 舌大, 質淡紅微燥, 苔
7) 脈診 : 沈滑數, 91회/분 7) 脈診 : 沈滑數, 91 times/min
8) 생활습관 : 식품연구원으로 재직중, 최근 2개월간 야근(저녁9~10시) 지속과 스트레스 증가로 가슴답답함이 심했음. 운동은 하지 않음. 8) Lifestyle: Working as a food researcher, over the past 2 months (9-10 p.m.) continued and increased stress caused severe chest discomfort. I don't exercise.
6 한약처방 및 생활관리6 Herbal medicine prescription and daily life management
6-1 한약 6-1 Herbal medicine
[표 11] 한약 처방 [Table 11] Herbal medicine prescription
6-2 생활관리6-2 Life management
1) 수면; 11시 이내에 잠을 잘 것1) sleep; go to bed by 11 o'clock
뇌, 망막은 오직 포도당만을 에너지로 사용한다. 뇌와 망막의 에너지원인 당의 사용량을 줄여주기 위해서 양질의 수면습관이 중요하다는 판단에서 밤 11시 이전에 취침하도록 하였다. The brain and retina use only glucose for energy. In order to reduce the amount of sugar, which is an energy source for the brain and retina, it was decided to go to bed before 11 p.m. in the judgment that a good sleep habit is important.
2) 음식; 정제된 탄수화물인 인스턴트 식품들(빵, 라면, 탄산음료등) 삼가할 것. 일반 한식은 충분히 식사하되, 천천히 씹어서 드실 것.2) food; Avoid instant foods that are refined carbohydrates (bread, ramen, soda, etc.). In general, eat enough Korean food, but chew it slowly.
3) 운동; 운동은 이미 충분한 상황이었고, 환자의 체력에 무리한 수준이라고 판단되어 1일 1시간 30분 정도 이상을 하지 않도록 지시하였다.3) exercise; Exercise was already sufficient, and it was judged that the patient's physical strength was too high, so he was instructed not to do more than 1 hour and 30 minutes a day.
7 경과사항7 Progress
1) 7월 5일(치료경과 14일) - 몸무게 83.7㎏ 1) July 5th (14 days after treatment) - Weight 83.7kg
혈압 : 145/100㎜Hg, 脈沈遲(맥박수 67회/분) Blood pressure: 145/100 mmHg, 脈沈遲 (pulse rate 67/min)
소화는 이전보다 잘되고, 수면은 11시 취침 ~ 6시 기상(소변으로 깨는 경우 줄음) 유지중이고, 운동은 실내자전거 매일 20분씩 하고 있었다. Digestion is better than before, sleep is maintained at 11 o'clock to 6 o'clock (wake up from urination is reduced), and he exercised for 20 minutes on an indoor bicycle every day.
2) 7월 19일(치료경과 28일) - 몸무게 81㎏ 2) July 19 (28 days after treatment) - Weight 81 kg
혈압 130/90㎜Hg, 脈沈遲(맥박수 66회/분) Blood pressure 130/90mmHg
소화 문제없었으나, 최근 과일 많이 섭취한 부분 확인되었다(복숭아,자두,체리,바나나). 수면 11시 취침 ~ 6시 기상(소변으로 인해 깨는 경우 가끔 발생) 유지중이었고, 업무과다로 인한 스트레스 여전하였다. 운동량은 매일 30분 ~ 1시간 걷고 있었다. There was no digestive problem, but it was confirmed that he ate a lot of fruit recently (peach, plum, cherry, banana). Sleeping 11 o'clock to 6 o'clock wake up (sometimes waking up due to urination) was maintained, and stress due to overwork was still there. The amount of exercise was walking for 30 minutes to 1 hour every day.
3) 8월 16일(치료경과 1개월 25일) - 몸무게 80.7㎏ 3) August 16th (1 month and 25 days after treatment) - Weight 80.7kg
혈압 120/75㎜Hg, 脈沈遲(맥박수 67회/분) Blood pressure 120/75 mmHg, 脈沈遲 (pulse rate 67/min)
소화 잘되고, 갈증 소실되었다. 한식위주로 식사 중이었고, 수면은 11시 ~ 12시 취침하여 6시 기상하였다(소변 안보고 더워서 한번 깸). Good digestion, thirst quenched. I ate mainly Korean food, went to bed between 11 and 12 o'clock and woke up at 6 o'clock (I woke up once because it was hot without urinating).
운동은 매일 실내자전거, 걷는 운동하였고, 주말에 등산 1시간씩 하였다. For exercise, indoor cycling and walking were exercised every day, and hiking was performed for 1 hour on weekends.
4) 9월 27일(치료경과 3개월) - 몸무게 78.6㎏ 4) September 27 (3 months after treatment) - Weight 78.6 kg
입마름, 갈증, 빈뇨 소실되었다. Dry mouth, thirst, and frequent urination disappeared.
5) 10월 24일(치료경과 4개월) - 몸무게 78.3㎏ 5) October 24 (4 months after treatment) - Weight 78.3 kg
10월 19일 서울모병원에서 실시한 건강검진 결과지를 가지고 내원하였다. 결과지 수치는 다음과 같았다. HbA1c 6.5%, 혈당 105㎎/㎗, 혈압 : 117/74㎜Hg 심전도 정상, 콜레스테롤 수치 호전 248㎎/㎗ →210㎎/㎗ On October 19th, he came to the hospital with the results of the medical examination conducted at Seoul Mo Hospital. The resulting figures were as follows. HbA1c 6.5%, blood sugar 105mg/dl, blood pressure: 117/74mmHg ECG normal, cholesterol level improved 248mg/dl →210mg/dl
6) 11월 22일(치료경과 5개월) - 몸무게 78.4㎏ 6) November 22 (5 months after treatment) - Weight 78.4 kg
수면은 12시 ~ 6시(중간에 깬적 없음)로 유지중이었고, 운동은 주 3회 실내 자전거 또는 걷기 하였다. Sleep was maintained between 12 o'clock to 6 o'clock (no waking up in the middle), and exercise was performed by indoor cycling or walking 3 times a week.
8) 2017년 1월 4일(치료경과 6개월 15일) - 몸무게 78.7㎏ 8) January 4, 2017 (6 months and 15 days after treatment) - Weight 78.7kg
수면은 12시 넘어 취침하였으나 중간에 깨지않고 일어난다 하였다. He went to bed after 12 o'clock, but woke up without waking up in the middle.
[표 12] 환자의 혈당, 요, 당화혈색소 변화 [Table 12] Changes in blood sugar, urine, and glycated hemoglobin in patients
상기 표에서 확인할 수 있는 바와 같이, 고혈당으로 당뇨병 진단이후 양약 복용후 피로감이 증가하여, 양약 복용 없이 한약과 생활 관리만으로 적극적으로 치료하여 신체적 제반증상의 소실과 함께 혈당, 당화혈색소, 요당, 케톤뇨의 수치를 모두 안정화 시켰다.As can be seen in the table above, after diagnosis of diabetes due to high blood sugar, fatigue increased after taking Western medicines, so without taking Western medicines, active treatment only with herbal medicines and lifestyle management resulted in the disappearance of all physical symptoms and reduced blood sugar, glycated hemoglobin, urine sugar, and ketonuria. All values were stabilized.
(5) Case study 5 CBH(M/39) 증례일지(5) Case study 5 CBH (M/39) case log
1 주소증1 address card
피로감, 고혈당, 지방간Fatigue, high blood sugar, fatty liver
2 과거력2 past history
혼합형 불안우울 장애로 3년전부터 신경정신과약 복용중I have been taking neuropsychiatric medication for 3 years for mixed anxiety-depressant disorder.
대구에서 심리상담 1~2주 1회 받고 있음(일반 심리 상담소)Psychological counseling in Daegu once every 1-2 weeks (General Psychological Counseling Center)
고혈압약 복용중(살로탄50mg, 4년전부터), Taking antihypertensive drugs (Salotan 50mg, from 4 years ago),
지방간치료제 아침 저녁 복용중 (4년전부터)I am taking a fatty liver treatment in the morning and evening (from 4 years ago)
2009년 2월에 혈당이 600mg/dl 정도, 체중감소가 심하여 당뇨약 복용 시작.In February 2009, he started taking diabetes medication because his blood sugar was about 600mg/dl and his weight loss was severe.
3 현병력3 current military
2016년 6월 24일 상기 주소증과 함께 당뇨약(제마메트서방정2550 아침1, 저녁1)을 복용중인데 혈당 조절이 되지 않는다고 한방 치료를 병행하고 싶어서 내원하였음. On June 24, 2016, I came to the hospital because I was taking diabetes medication (Zemamet Seo-Release Tablet 2550 morning 1, evening 1) with the above dyslexia and wanted to receive oriental treatment at the same time as my blood sugar could not be controlled.
내원당시 현재 당뇨약을 처방받고 있는 모 내과에서의 4월 27일에 시행한 검사결과지를 가지고 오셨음.At the time of admission, he came with the test result sheet that was performed on April 27 at the mother's internal medicine department, who is currently taking diabetes medication.
4. 주요검사소견4. Major inspection findings
1) 2016년 4월 27일 서울 모 내과 검사 1) April 27, 2016 Seoul Medical Examination
공복 혈당 : 161㎎/㎗, HbA1c 7.8% Fasting blood sugar: 161mg/dl, HbA1c 7.8%
GOT : 82 IU/L, GPT: 51 IU/L, 중성지방: 156 mg/dl GOT: 82 IU/L, GPT: 51 IU/L, triglycerides: 156 mg/dl
2) 2016년 6월 24일 본원 검사 2) Inspection at the hospital on June 24, 2016
혈압 130/90 mmHg 혈당; 363 mg/dl(식후2시간 23분) HbA1c 10% blood pressure 130/90 mmHg blood sugar; 363 mg/dl (2 hours 23 minutes after meals) HbA1c 10%
5 초진소견5 First visit
1) 消化器系 1) 消化器系
근무 여건상 음식을 빨리 먹고, 식사 시간이 불규칙하다 I eat quickly due to working conditions, and meal times are irregular.
가끔 속쓰림(+), 心下(+), 허기짐은 없다. Sometimes there is no heartburn (+), 心下 (+), or hunger.
2) 飮酒 : 원래부터 음주를 하지 않는다. 2) 飮酒: I do not drink from the beginning.
3) 睡眠 : 2교대 근무로 불규칙, 수면총양은 6~8시간. 3) 睡眠: Irregular with 2 shifts, the total amount of sleep is 6-8 hours.
4) 汗 : 전신에서 많이 흘린다. 4) 汗: A lot of shed from the body.
5) 大便 : 1회/일, 불편함 없음 5) 大便: 1 time/day, no discomfort
6) 舌診 : 舌大, 質燥, 白苔有 6) 舌診: 舌大, 質燥, 白苔有
7) 脈診 : 沈緊數, 102회/분 7) 脈診 : 沈緊數, 102 times/min
8) 생활습관 : 청송교도소에서 근무하는 교도관으로써 긴장, 스트레스가 많고 2교대 근무로 불규칙한 생활패턴 8) Lifestyle: As a prison guard at Cheongsong Prison, there is a lot of tension and stress and irregular life patterns due to working in two shifts.
6. 한약처방 및 생활관리6. Herbal medicine prescription and daily life management
6-1 한약 6-1 Herbal medicine
[표 13] 한약 처방 [Table 13] Herbal medicine prescription
6-2 생활관리 1) 수면; 근무여건상 일정한 수면패턴이 어렵지만, 가급적 충분한 잠을 자도록 지도6-2 Life management 1) Sleep; Although it is difficult to have a consistent sleep pattern due to working conditions, instruct them to get enough sleep as much as possible.
2) 음식; 정제된 탄수화물인 인스턴트 식품들(빵, 라면, 탄산음료등) 삼갈 것. 일반 한식은 충분히 식사하되, 천천히 씹어서 드실 것. 2) food; Avoid instant foods that are refined carbohydrates (bread, ramen, soda, etc.). In general, eat enough Korean food, but chew it slowly.
3) 운동; 산책을 통해 심리적 안정과 기분 전환을 목적으로 운동할 것. 3) exercise; Exercise for the purpose of psychological stability and mood change through walking.
7. 경과사항7. Progress
1) 2016년 7월 27일 (치료 1달 경과 ) - 체중 75.3 Kg 1) July 27, 2016 (one month after treatment) - Weight 75.3 Kg
혈압 120/85mmHg 혈당; 183 mg/dl(식후2시간 10분) blood pressure 120/85 mmHg blood sugar; 183 mg/dl (2 hours 10 minutes after meals)
수면중 깨는 횟수가 줄었다고 말함. He said that the number of times he wakes up during sleep is reduced.
간수치 확인을 위해 혈액검사를 받도록 지도 Instruct them to take blood tests to check liver levels
7월 29일 혈액검사 결과지 팩스로 보냄(간수치는 정상, 중성지방 수치 상승) On July 29th, blood test results are sent by fax (liver level is normal, triglyceride level rises)
GOT : 27 IU/L, GPT: 25IU/L, 중성지방: 309 mg/dl GOT: 27 IU/L, GPT: 25 IU/L, triglycerides: 309 mg/dl
2) 9월 1일 - 체중 73.5 Kg 2) September 1st - Weight 73.5 Kg
혈압 112/98mmHg 혈당; 269 mg/dl(식후1시간 10분) blood pressure 112/98 mmHg blood sugar; 269 mg/dl (1 hour and 10 minutes after meals)
체중이 2 Kg 감소했고, 기력이 좋아졌다. I lost 2 kg of weight and my energy improved.
3) 9월 21일 - 체중 73.4 Kg 3) September 21 - Weight 73.4 Kg
근무 부서가 이동하여 스트레스가 많았다 There was a lot of stress because the work department moved
4) 10월 24일 - 체중 72.9 Kg 4) October 24 - Weight 72.9 Kg
한의원 내원시 혈당 149 mg/dl 확인되어 유의미하게 혈당이 내려감. When visiting an oriental clinic, blood sugar was found to be 149 mg/dl, and blood sugar dropped significantly.
한의원 내원하기 전에 서울 모 내과 방문하고 옴(당뇨약 글리멜 추가 처방됨) Before visiting the oriental medicine clinic, he visited a medical department in Seoul and came (additionally prescribed diabetic drug Glimel).
5) 11월 25일 - 체중 75.5 Kg 5) November 25 - Weight 75.5 Kg
혈당 : 140㎎/㎗(식후 1시간 12분), HbA1c 8.6% 수치가 계속 좋아지고 있음 Blood sugar: 140 mg/dL (1 hour and 12 minutes after a meal), HbA1c 8.6% level continues to improve
10월 24일에 내과에서 처방받은 추가 당뇨약인 글리멜정은 1주일 3~4회 복용하고 있음 Glimel tablets, an additional diabetes drug prescribed by the internal medicine clinic on October 24, are being taken 3 to 4 times a week.
불편사항 없으나, 글리멜정 복용 이후 체중이 증가하는 것 같다고 함. There are no complaints, but he said that he seems to have gained weight after taking Glimel tablets.
11월 21일 직장검강검진 받았고 혈압 110/70mmHg 공복혈당 128 mg/dl On November 21st, I had a rectal examination and my blood pressure was 110/70mmHg, fasting blood sugar 128 mg/dl.
GOT : 24 IU/L, GPT: 40 IU/L, 중성지방: 229 mg/dl 확인되었다. GOT: 24 IU/L, GPT: 40 IU/L, triglyceride: 229 mg/dl were confirmed.
6) 12월 26일 - 체중 77.5 Kg 6) December 26 - Weight 77.5 Kg
글리멜 복용이후 체중이 증가하고 피로감이 증가하며, 저혈당 증세를 보여서 복용을 중단했다고 함. 당뇨약은 처음과 같이 제마메트만 복용중. After taking Glimel, he experienced weight gain, increased fatigue, and symptoms of hypoglycemia, so he stopped taking it. As for diabetes medication, I am taking only Zemamet.
脈沈緊數 ,舌苔無, 대변 1일 1회 정상 脈沈緊數, 舌苔無, stool once a day
7) 2017년 1월 16일 - 체중 79.1Kg 7) January 16, 2017 - Weight 79.1Kg
양약 복용을 줄였다고 함. He said that he reduced his drug intake.
당뇨약은 아침 저녁 제마메트 2550 1알씩 복용하던 것을 저녁에만 1알씩 복용, For diabetes, take 1 tablet of Zemamet 2550 each in the morning and evening, and take 1 tablet each in the evening.
글리멜은 월, 수, 금요일 아침에 1/2알 복용했음 Glimel was taken 1/2 tablet in the morning of Monday, Wednesday, and Friday.
혈압약은 1/2로 줄여서 복용중 I am taking the blood pressure medicine by reducing it by 1/2.
신경안정제는 야간근무하는 날은 복용하지 않고 있음 Nerve sedatives are not taken on night shift days.
8) 2월 24일 - 체중 80Kg 8) February 24 - Weight 80Kg
혈당 134 mg/dl (식후 1시간) Blood sugar 134 mg/dl (1 hour after meal)
내과에서 당뇨 처방이 바뀌어서 양약 복용 패턴이 바뀌었음 Diabetes prescription has changed in internal medicine, so the pattern of taking Western medicine has changed
글리멜정 1mg 은 아침에 2일에 한번 1/2알 복용중 Glimel tablet 1mg is taking 1/2 tablet once every 2 days in the morning
제미글로정 50mg 은 매일 아침에 1알 복용중 Zemiglo 50mg is taking 1 tablet every morning
다이아벡스 500은 아침 1, 저녁1 복용중 Diabex 500 is taking 1 in the morning and 1 in the evening.
포시가 10mg 도 처방되었으나, 복용하지 않았음. 혈당은 최근 내려가는데 갑자기 내과에서 당뇨약을 더 많이 처방해서, 환자가 검색해보니 포시가에 대한 부작용이 신경쓰여서 복용을 안했음. Posiga 10mg was also prescribed, but not taken. My blood sugar has recently gone down, but the internal medicine doctor has prescribed more diabetes drugs, so when the patient searched for it, he was concerned about the side effects of Forxiga, so he didn't take it.
[표 14] 환자의 혈당, 요당 및 당화혈색소 변화 [Table 14] Changes in blood sugar, urine sugar, and glycated hemoglobin in patients
상기 확인할 수 있는 바와 같이, 혈당, 요당 및 당화 혈색소 측면에서 상당히 개선된 수치를 나타내었다. 특히, 양약 복용 과정중에 어느 순간 혈당이 조절되지 않고, 복용약은 계속 증가하던 환자에게 한약 치료를 통해 혈당조절에 도움을 주고, 컨디션 및 몸의 증상 개선에 도움을 주는 증례이다.As can be seen above, significantly improved values were shown in terms of blood sugar, urine sugar, and glycated hemoglobin. In particular, it is a case in which blood sugar is not controlled at some point during the course of taking Western medicines, and the medication is helping to control blood sugar through herbal treatment to a patient who continues to increase, and helps to improve the condition and symptoms of the body.
초기 높았던 간수치도 한약 투여이후 정상으로 회복되는 결과는 적극적인 한약 치료가 환자의 혈당 조절과 더불어 몸의 개선에 큰 역할을 할 수 있음을 보여준다.The results of the initial high liver level returning to normal after herbal medicine administration shows that active herbal medicine treatment can play a big role in improving the body as well as controlling the patient's blood sugar.
(6) Case study 6 LHJ(F/50) 증례일지(6) Case study 6 LHJ (F/50) case log
1. 주소증 ; 足痺症, 疲勞, 糖尿1. Address card;足痺症, 疲勞, 糖尿
2. 과거력 : 5년전 백내장 진단후 안과 정기적 검진중 2. History : After cataract diagnosis 5 years ago, regular ophthalmology examination
2016년 과민성 방광염 진단후 1년동안 양약 복용 After diagnosis of overactive cystitis in 2016, taking Western medicine for 1 year
1년전부터 발목의 물주머니?가 신경을 누르고 있다는 진단과 함께 진통제 복용하다가 최근 1개월간 복용중단(양약 부작용에 대한 걱정으로) I was taking painkillers with the diagnosis that the water bag in my ankle was pressing on the nerve since a year ago, and I stopped taking it for the last 1 month (due to concerns about side effects of Western medicine)
3. 현병력3. Current military history
상기자는 만 50세의 여성(160cm/85.1㎏)으로 교회 업무를 하고 있다. The person mentioned above is a 50-year-old woman (160cm/85.1kg) who works in the church.
발목 통증으로 진통제를 복용하는 과정중, 엄지손가락 屈伸不利로 류마티스 내과의원에 방문하여 평소에 갈증과 소변을 자주 본다는 환자의 불편 증상에 대한 진료와 함께 혈액검사를 진행하였다. In the process of taking painkillers for ankle pain, he visited a rheumatologist with his thumb 屈伸不利 and performed a blood test along with treatment for the patient's discomfort symptoms such as thirst and frequent urination.
2018년 4월4일 내과 혈액검사 결과 혈당392㎎/㎗, HbA1c 13.5 %, 요당 양성(++)으로 당뇨병 진단후 3종류의 당뇨약 복용을 시작하였다.On April 4, 2018, as a result of the internal medicine blood test, blood sugar 392 mg/dl, HbA1c 13.5%, and urine sugar positive (++) were diagnosed, and three types of diabetes drugs were started.
당뇨약 복용중 저혈당이 와서 당뇨약을 한알을 줄였으나, 피로감과 다리저림과 평생 당뇨약을 복용해야 한다는 걱정으로 10일간 당뇨약을 자의적으로 중단하고 본원에 내원하였다. Hypoglycemia occurred while taking the diabetes medicine, so I reduced the diabetes medicine by one tablet, but I arbitrarily stopped the diabetes medicine for 10 days due to fatigue, numbness in my legs, and worries that I would have to take diabetes medicine for the rest of my life.
4 주요 검사소견 4 Major findings
1) 2018년 4월 4일 류마티스 내과 검사 결과 1) Results of rheumatology examination on April 4, 2018
식후혈당 392㎎/㎗, HbA1c 13.5 %, 요당 양성(++), Postprandial blood sugar 392 mg/dL, HbA1c 13.5 %, urine sugar positive (++),
2) 2018년 6월 18일 본원 검사 결과 2) June 18, 2018 inspection results
식후혈당 136 ㎎/㎗(식후3시간 30분), HbA1c 7.0 %, 요당 음성(-), Postprandial blood glucose 136 mg/dl (3 hours 30 minutes after meals), HbA1c 7.0%, urine glucose negative (-),
5. 초진소견5. First visit
1) 消化器系; 최근 消化不良, 心下滿(+) 1) 消化器系; Recent change of heart (+)
2) 飮酒 : 거의 안한다. 2) 飮酒: Almost never.
3) 睡眠 : 11시 ~12시 취침 ~ 5시 기상 ( 5시 20분 예배) 3) 睡眠: 11am to 12pm, bedtime to 5pm (worship service at 5:20pm)
4) 汗 : 얼굴에 땀 많이 흘림 4) 汗: sweating profusely on the face
5) 大便 : 1회/일 변비로 힘들다가 유산균먹고 괜찮아짐. 5) 大便: Once/day I was constipated and it was hard, but I got better after eating lactic acid bacteria.
6) 舌診 : 舌大, 白裂有 찐득한 침 6) 舌診 : 舌大, 白裂有 sticky saliva
7) 脈診 : 沈緊,數 91회/1분 7) 脈診 : 沈緊, 數 91 times/1 min
8) 생리 ; 3년전 생리하고, 올해 4월에 한번 생리했음. 8) menstruation; I had my period 3 years ago, and I had my period once in April of this year.
9) 생활습관 : 평상시 인간 관계에서 스트레스가 많다. 9) Lifestyle: There is a lot of stress in human relationships.
빵을 자주 먹었는데, 당뇨 진단후 빵을 많이 줄였다. I ate bread often, but after my diabetes diagnosis, I cut down on bread a lot.
음식 관리가 어렵다. Food management is difficult.
6 한약처방 및 생활관리6 Herbal medicine prescription and daily life management
6-1 한약 6-1 Herbal medicine
[표 15]한약 처방 [Table 15] Herbal medicine prescription
6-2 생활관리 지도6-2 Living management guidance
1) 수면; 11시 이내에 잠을 잘 것1) sleep; go to bed by 11 o'clock
뇌, 망막은 오직 포도당만을 에너지로 사용한다. 뇌와 망막의 에너지원인 당의 사용량을 줄여주기 위해서 양질의 수면습관이 중요하다는 판단에서 밤 11시 이전에 취침하도록 하였다. The brain and retina use only glucose for energy. In order to reduce the amount of sugar, which is an energy source for the brain and retina, it was decided to go to bed before 11 p.m. in the judgment that a good sleep habit is important.
2) 음식; 정제된 탄수화물인 인스턴트 식품들(빵, 라면, 탄산음료등) 삼가할 것. 일반 한식은 충분히 식사하되, 천천히 씹어서 드실 것.2) food; Avoid instant foods that are refined carbohydrates (bread, ramen, soda, etc.). In general, eat enough Korean food, but chew it slowly.
3) 운동; 모니터를 보는 중간에 자주 스트레칭을 해주고, 시간나면 산책을 하도록 지도.3) exercise; In the middle of looking at the monitor, stretch often, and teach them to take a walk when they have time.
4) 양약; 본인이 복용하지 않을려는 의지가 강하여 계속 중단하면서 한약 치료 진행.4) Western medicine; He continued to stop taking herbal medicine because he had a strong will not to take it.
7 경과사항7 Progress
1) 7월 2일(치료경과 14일) - 몸무게 86.4㎏ 1) July 2nd (14 days after treatment) - Weight 86.4kg
혈당 139㎎/㎗( 식후3시간7분), 요당 음성(-), Blood sugar 139㎎/㎗ (3 hours 7 minutes after meals), urine sugar negative (-),
6월 10일 이후 현재까지 당뇨약 및 진통제 복용중인 것 없음 No diabetic or painkillers have been taking since June 10th
수면 시간 개선 노력중(11시쯤 취침; 12시 잠듦) Efforts to improve sleep time (go to bed around 11 am; go to sleep at 12 pm)
좌골신경통 관련 동네 한의원에서 침치료 받았음. I received acupuncture treatment at a local oriental clinic related to sciatica.
2) 7월 31일(치료경과 1개월 13일) - 몸무게 83.7㎏ 2) July 31 (1 month and 13 days of treatment) - Weight 83.7kg
혈당 101㎎/㎗(식후2시간) 요당 음성(-) Blood sugar 101mg/dl (2 hours after meals) Urine glucose negative (-)
足痺症 거의 없음. 수면중 더워서 wkadf 깨고 소변보는 것 없음. 足痺症 almost none. No need to wake up wkadf and urinate because it's hot during sleep.
좌골신경통 관련 동네 한의원에서 약침 시술 1회 받음. Received acupuncture treatment once at a local oriental clinic related to sciatica.
3) 8월 27일(치료경과 2개월 9일) - 몸무게 83.4㎏ 3) August 27 (2 months and 9 days after treatment) - Weight 83.4 kg
혈당 139mg/㎗(식후2시간 30분), 요당 음성(-) Blood sugar 139mg/㎗ (2 hours 30 minutes after a meal), urine sugar negative (-)
8월13일 ~8월21일 해외 여행 다녀옴. From August 13th to August 21st, I went on an overseas trip.
8월 23일 보건소에서 혈액검사후 오늘 검사결과지 가져옴 After a blood test at the public health center on August 23, I brought the test result today.
보건소 혈액검사 결과 식후혈당 153mg/㎗, HbA1c 6.5 % Postprandial blood glucose 153mg/dL, HbA1c 6.5%
4) 9월 11(치료경과 2개월 23일) - 몸무게 84.2㎏ 4) September 11 (2 months and 23 days of treatment) - Weight 84.2kg
혈당 169㎎/㎗(식후2시간30분) 요당 음성(-), Blood sugar 169㎎/㎗ (2 hours 30 minutes after meals) Urine sugar negative (-),
1주일전부터 감기증상 있으나 약을 복용하지 않고 있음. I have had cold symptoms since 1 week ago, but I am not taking any medications.
5) 10월 4일(치료경과 3개월16일) - 몸무게 83.7㎏ 5) October 4th (3 months and 16 days after treatment) - Weight 83.7kg
혈당 126㎎/㎗(식후4시간), 요당 음성(-) HbA1c 6.4 % Blood sugar 126 mg/dl (4 hours after meals), urine glucose negative (-) HbA1c 6.4 %
얼굴에 열이 나는 갱년기 증상이 있음. I have menopausal symptoms with a fever on my face.
과거 방광염 진단 받을 초기의 방광쪽 우리한 느낌 있음 There is a feeling of discomfort on the bladder side in the early stages of being diagnosed with cystitis in the past
컨디션 양호하고 특별하게 당뇨관련 불편증상 없음. He was in good condition and had no symptoms related to diabetes.
[표 16] 환자의 혈당, 요당 및 당화 혈색소 변화[Table 16] Changes in blood glucose, urine glucose and glycated hemoglobin in patients
상기 확인할 수 있는 바와 같이, 양약을 끊고 한약 처방만으로 혈당, 요당 및 당화혈색소에 상당한 개선 효과를 나타내었다. As can be seen, significant improvement in blood sugar, urine sugar, and glycated hemoglobin was achieved only by discontinuing the Western medicine and prescribing the herbal medicine.
특히, 당뇨약에 대한 기피감이 심한 여성 환자를 한약 복용과 생활관리만으로 혈당을 조절하며, 몸의 제반증상을 조절한 케이스로 우수한 효과를 나타내었다. In particular, it showed an excellent effect in the case of controlling the blood sugar of a female patient with a strong sense of reluctance to diabetic drugs by taking oriental medicine and managing daily life, and controlling various symptoms of the body.
상기 증례 case들에서 확인할 수 있는 바와 같이, 본 발명에 따른 복합 추출물은 다양한 임상적 소견을 나타내는 환자군들 모두에서 우수한 당뇨 개선 효과를 나타내었다. 이러한 개선 효과는 본 발명에 따른 복합 추출물의 우수한 치료 및 개선 효과를 보여준다. As can be seen from the above case cases, the complex extract according to the present invention exhibited an excellent diabetes improvement effect in all patient groups showing various clinical findings. This improvement effect shows excellent treatment and improvement effects of the complex extract according to the present invention.
Claims (10)
The method of claim 6, wherein the saengjihwang, ginseng, gwaruin, mokdanpi, gardenia, indongdang, and byeolgapgyo complex extract is 1 to 5 parts by weight of saengjihwang, 1 to 5 parts by weight of ginseng, 0.5 to 4 parts by weight of ginseng based on 100 parts by weight of water. A food composition for the prevention or improvement of diabetes comprising 0.5 to 3 parts by weight of mulberry skin, 0.3 to 3 parts by weight of gardenia, 0.3 to 3 parts by weight of ginseng, and 0.1 to 2 parts by weight of byeolgap bridge.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200071087A KR20210154312A (en) | 2020-06-11 | 2020-06-11 | Combination Extract for improving or treating diabetes comprising Rehmanniae Radix Recens, and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200071087A KR20210154312A (en) | 2020-06-11 | 2020-06-11 | Combination Extract for improving or treating diabetes comprising Rehmanniae Radix Recens, and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20210154312A true KR20210154312A (en) | 2021-12-21 |
Family
ID=79165238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200071087A KR20210154312A (en) | 2020-06-11 | 2020-06-11 | Combination Extract for improving or treating diabetes comprising Rehmanniae Radix Recens, and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20210154312A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101095467B1 (en) | 2009-07-30 | 2011-12-16 | 주식회사 유니베라 | Pharmaceutical composition comprising ACTIValoe DM, or a mixture of ACTIValoe DM and chrome for preventing or treating type II diabetes |
KR101679117B1 (en) | 2013-05-24 | 2016-11-24 | 주식회사 나노바이오텍 | Novel Compound Isolated from Quamoclit and Composition for Preventing or Treating Diabetes Comprising the Same |
-
2020
- 2020-06-11 KR KR1020200071087A patent/KR20210154312A/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101095467B1 (en) | 2009-07-30 | 2011-12-16 | 주식회사 유니베라 | Pharmaceutical composition comprising ACTIValoe DM, or a mixture of ACTIValoe DM and chrome for preventing or treating type II diabetes |
KR101679117B1 (en) | 2013-05-24 | 2016-11-24 | 주식회사 나노바이오텍 | Novel Compound Isolated from Quamoclit and Composition for Preventing or Treating Diabetes Comprising the Same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103690784B (en) | The Chinese medicine composition for the treatment of Complicating with Hypentersion nephropathy and preparation method | |
KR101987418B1 (en) | A composition comprising herbal mixture extract for neuroprotection | |
KR100923043B1 (en) | Blood pressure therapeutic agent for chinese medicine and manufacture method thereof | |
KR101765246B1 (en) | Composition for preventing and improving sex hormone-related disease | |
CN107494817A (en) | A kind of hypoglycemic tea | |
CN101336965B (en) | Chinese prepared medicine for improving sugar tolerance and reducing blood sugar and preparation method thereof | |
KR101989739B1 (en) | Composition for preventing or treating diabetes mellitus comprising Rorippa globosa extracts | |
KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
KR20090075343A (en) | Chinese medicine compositions for anti-diabetic and manufacture method thereof | |
KR100850503B1 (en) | Composition for improving erectile dysfunction and erection maintenance containing the extract of crude drug complex | |
CN107712890A (en) | A kind of antitoxic heart-soothing and sedative cream taste and preparation method thereof | |
KR20210154312A (en) | Combination Extract for improving or treating diabetes comprising Rehmanniae Radix Recens, and preparation method thereof | |
CN105535587A (en) | Traditional Chinese medicinal preparation for treating heart and kidney disharmony type palpitation and insomnia and preparation method of traditional Chinese medicinal preparation | |
KR100638344B1 (en) | Composition comprising the crude drug extract for improving eye symptoms of VDT syndrome | |
CN103110675A (en) | Soft capsule for improving alimentary anemia and preparation method thereof | |
CN104524359B (en) | A kind of Chinese medicine composition, its preparation method and application | |
CN108452079B (en) | Methods and compositions for delaying senescence, inhibiting tumor cell growth, and improving microcirculation | |
CN106540011A (en) | The pharmaceutical composition of preventing and treating senile osteoporosis | |
CN100560085C (en) | A kind of Chinese herbal medicine and uses thereof | |
KR100894029B1 (en) | The ginseng fiower composition, that prevention and remedy cure to sgar diabtes | |
KR20090013956A (en) | Composition for improving erectile dysfunction and erection maintenance comprising the extract of crude drug complex | |
CN106620056A (en) | Pharmaceutical composition for treating diabetic retinopathy | |
CN106822206A (en) | It is a kind of to treat pharmaceutical composition of neurodermatitis and preparation method thereof | |
CN104352974A (en) | Ciliatenerve knotweed root-containing traditional Chinese medicine composition for treating diabetes | |
CN103356984B (en) | Traditional Chinese medicine composition for preventing and treating female iron deficiency anemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E601 | Decision to refuse application |